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ABSTRACT

TYROSYL PROTEIN PHOSPHORYLATION IN HUMAN
BONE CELLS: ITS POTENTIAL ROLE IN MEDIATING
FLUORIDE-INDUCED OSTEOBLAST PROLIFERATION

by
Alan Blair Thomas

This dissertation was designed to test the hypothesis that fluoridestimulated osteoblast proliferation is mediated by specific inhibition
of a phosphotyrosyl protein phosphatase, resulting in increased steady
state levels of tyrosyl phosphorylation of key cellular proteins.
Cellular levels of tyrosyl phosphorylation were determined by an
immunoblot detection assay in which cellular proteins were separated
by SDS-PAGE, transblotted to nitrocellulose membranes and the
phosphotyrosyl proteins were identified by anti-phosphotyrosine
monoclonal antibodies.

The relative amount of tyrosyl phosphorylation

was quantitated by laser densitometric analysis of the autoradiograms.
This method showed that fluoride induced dose- and time-dependent
changes in the level of tyrosyl phosphorylation of proteins with
apparent M.W.’s of 244, 220, 170, 96, 62, 48, 34 and 32kD.

These

changes in tyrosyl phosphorylation appeared to be determining factors
in mediating fluoride induced osteoblast proliferation based on the
following: a) Some of the fluoride-dependent changes in tyrosyl

phosphorylation appeared to exhibit dose-dependent relationships
similar to fluoride induced bone cell mitogenesis (i.e. 220, 34 and
32kD),

b) Several other bone cell mitogens stimulated tyrosyl

phosphorylation of similar molecular weight proteins as fluoride,
suggesting that these proteins are important mediators of bone cell
proliferation (e.g. vanadate 244, 220, 96, 48, 34 and 32kD; IGF-I 220,
170 and 96kD; PDGF 244 and 220kD; EGF 244, 220, 170 and 96kD; IGF-II
220 and 96kD; electromagnetic field exposure 220 and 96kD),

and c)

Cells which did not respond to fluoride mitogenical1y were shown to
have no significant fluoride-dependent changes in their levels of
tyrosyl phosphorylation.

With regards to the mechanism by which

fluoride increased tyrosyl phosphorylation, the time course for
fluoride-dependent tyrosyl phosphorylation was not compatible with
tyrosyl kinase activation (i.e. several hours were required to observe
fluoride-dependent tyrosyl phosphorylation while the tyrosyl kinase
activating growth factors elicited immediate increases in steady state
levels of tyrosyl phosphorylation).

Taken together, these data are

consistent with the hypothesis that fluoride induced osteoblast
proliferation is mediated by an increase in the steady state level of
tyrosyl phosphorylation via phosphotyrosyl protein phosphatase
inhibition.
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CHAPTER ONE

INTRODUCTION
I.

Osteoporosis
Osteoporosis is defined as a disease which manifests itself as a

generalized decrease in bone density which predisposes people to
fractures [1].

In the United States at least 25 million people are

affected by osteoporosis at an annual cost of $10 billion [2,3].
Osteoporotics suffer from 1.5 million fractures each year, including
250,000 hip fractures which have a 10-15% mortality rate within one
year of occurrence [4].

Clearly, osteoporosis is a significant

disease for which better treatments need to be aggressively pursued
[2,4].
One of the key factors which determines bone strength is bone
density [5,6], and bone density is maintained by the dynamic balance
between bone resorption and bone formation.

Bone resorption is

mediated by osteoclasts [7], and osteoblasts are responsible for bone
formation [8].

In a healthy adult skeleton, bone formation equals

bone resorption, and net bone volume is maintained.

As a consequence

of aging and in certain diseases, such as osteoporosis, bone
resorption exceeds bone formation and net bone volume is decreased.
If the bone loss is too rapid, or if it occurs over a prolonged period
of time, the bone density may fall below the fracture threshold* [9].
*The fracture threshold is defined as the bone density below which results in a significant increase
in the risk of obtaining a non-stress fracture. In females, this value has been determined to be a
spinal density of 100mg/cm3 while no value has been clearly set for males [9],
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If this occurs, the risk of fractures increases dramatically and the
skeleton may be described as osteoporotic.
Currently available treatments for osteoporosis are intended to
increase bone volume by inhibiting bone resorption and/or stimulating
bone formation [2].

Antiresorptive agents such as estrogens,

bisphosphonates and calcitonin are probably best suited for
maintaining the bone density and preventing it from decreasing below
the fracture threshold [10].

When bone density is below the fracture

threshold, inhibiting resorption may prevent further bone loss, but
the skeleton is already at an increased risk for fracture.

Therefore,

once the bone density has fallen below the fracture threshold and
osteoporosis has been established, bone formation must be stimulated
to increase the bone density and decrease the fracture rate [10].
Agents currently available to stimulate bone formation include
androgens, parathyroid hormone and fluoride [11-15], with fluoride
being recognized as the single most effective agent to increase the
spinal bone density in osteoporotics [13-20].

II.

Clinical Effects of Fluoride
Fluoride has been shown to increase bone density in the

osteoporotic spine [2,13].

It is believed that this increase in bone

density is responsible for fluoride’s ability to decrease the
incidence of vertebral crush fractures.

Histological data indicate

that fluoride increases bone volume by stimulating osteoblast
proliferation [21].

While previous in v/tro studies have demonstrated

that fluoride can be mitogenic for human osteoblasts [22-30], some
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laboratories have been unable to demonstrate the in vitro osteogenic
effects of fluoride [31,32].

The inability to detect consistent

mitogenic effects of fluoride could be due to the fact that fluoride’s
effects may be influenced by other factors (such as phosphate
concentration in the medium [22,33], cell density [25], availability
of endogenous growth factors [22], or other yet-to-be identified
variables).

The evidence that fluoride can be mitogenic for

osteoblasts both in vivo and in vitro is, nevertheless, compelling.
While fluoride is now generally accepted as a bone cell mitogen, the
biochemical mechanism by which fluoride induces osteoblast
proliferation has not yet been clearly defined.

The goal of this

dissertation is to define the biochemical mechanism by which fluoride
stimulates osteoblast proliferation.

III.

Cellular Effects of Fluoride

1) Membrane Permeability to Fluoride
Before any discussion of how fluoride induces osteoblast
proliferation can take place, it must first be determined whether or
not fluoride can cross the plasma membrane.

This is relevant because

it will provide clues as to how fluoride is functioning.

For example,

if plasma membranes are impermeable to fluoride then fluoride may be
inducing cellular proliferation by acting extracellularly on a cell
surface receptor.

If fluoride can cross the plasma membrane then it

is most likely going to act intracellularly by influencing enzyme

4
activities.

This concept is based on the observations that fluoride

interacts with many enzymes in vitro (Table 1).
Several lines of evidence demonstrate that cellular membranes are
not only permeable to fluoride, but that fluoride entry into cells is
rapid, perhaps through passive diffusion:

1) Plasma membranes of

human skin fibroblasts are permeable to fluoride, and an equilibrium
between intracellular and extracellular
within 2 minutes [41,42].
to fluoride [39,43].

fluoride is established

2) Red blood cell

membranes are permeable

3) It has been shown that muscle, liver and

tendon cells allow penetration of fluoride into the intracellular
compartment [44].

And 4) fluoride has been shown to cross synthetic

lipid bilayers [45].
While the literature shows that fluoride crosses cellular
membranes, the mechanism of fluoride’s transmembrane migration has not
been clearly defined.

It has been suggested that fluoride crosses

plasma membranes by passive diffusion of hydrogen fluoride [42,45].
This model is primarily based on the observation that fluoride
transmembrane migration is pH dependent, with fluoride entry into
cells

facilitated by lowering the pH of the extracellular medium

[42,45].

While the passive diffusion model for fluoride transmembrane

migration is not perfect, it is currently the most widely accepted
mechanism describing fluoride’s entry into cells.

5

TABLE 1
Effect of fluoride on various cellular enzymes.
Effect

Enzyme

FF1uoridel

HCC^-ATPase

1|iM and 5|iM activated

[34]

Na+,K+-ATPase

10|lM
300|iM

activated
inhibited

[34]
[34]

Ca++,Mg++-ATPase

10uM

inhibited

[34]

[35]
[29]
[36]
[29]
[29]
[29]
[29]
[29]
[29]
[29]
[29]
[37]
[38]

Ref.

acid phosphatases derived from:
human osteoblasts
mouse osteoblasts
bovine bone
chick tibia
chick kidney
chick muscle
chick brain
chick skin
chick heart
chick liver
chick intestine
human prostate
osteoclasts

12.7 pM
20pM
10-1OOpM
17pM
40 pM
1.61mM
3.13mM
3.97mM
4.27mM
4.40mM
12.74mM
10mM
0.55mM

50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
50%
98%
50%

adenylate cyclase

10mM

5.4 fold stimulation [29]

pyrophosphatase

1mM

90% inhibition

[39]

catalase

5mM

50% inhibition

[39]

cholinesterase

lOmM

50% inhibition

[39]

glutamine synthetase

10mM

50% inhibition

[39]

glucose dehydrogenase

10mM

30-40% inhibition

[39]

phosphoseryl protein
phosphatase

10-50mM

50% inhibition

[40]

acetyl phosphatase

50mM

50% inhibition

[39]

glucuronidase

238mM

complete inhibition [39]

alkaline phosphatase

500mM

50% inhibition

inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition
inhibition

[39]
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2) Dose Dependency of Fluoride Induced Cell
Proliferation
Micromolar concentrations of fluoride induce osteoblast
proliferation in a diphasic manner (Figure 1).

The micromolar

concentration range for fluoride induced osteoblast mitogenesis should
be emphasized, since it is known that millimolar concentrations of
fluoride affect certain cellular systems (i.e. activation of cAMP,
inhibition of serine/threonine phosphatases, etc.), however,
millimolar concentrations of fluoride are not mitogenic for
osteoblasts.

In the micromolar range, the in vitro effective doses of

fluoride appear to vary depending on the type of medium used to
culture the cell monolayers (see also Figure 1).

In DMEM,

concentrations of fluoride below 25pM are ineffective, while
concentrations above 400pM tend to be inhibitory.

In BGJ^ medium,

mitogenic concentrations of fluoride fall between IpM and lOOpM.
The concentrations of fluoride which usually result in maximal
stimulation of osteoblast proliferation are, approximately, lOOpM in
DMEM and 20pM in BGJb medium [23,29, and Figure 1].

The shift in

fluoride’s mitogenic dose-dependent curve between the two media may be
related to the phosphate concentration (DMEM has 1.2 mM phosphate,
BGJb has 1.8 mM phosphate),

This conclusion is supported by the

observation that decreasing the phosphate concentration of BGJb medium
to 1.2mM resulted in a shift of fluoride’s dose-dependent curve to
concentrations comparable to those normally observed in DMEM [22].

7

Figure 1. Graph depicting the diphasic nature of fluoride
induced cell proliferation and the effect of different media on
fluoride’s dose-response curve. These data show the
diphasic dose response of fluoride induced osteoblast-line
cell mitogenesis. DMEM contains 1.2mM phosphate while BGJj-,
contains 1.8mM phosphate. It is important to point out the
effect phosphate concentration has on shifting fluoride’s
diphasic mitogenic curve, and it has been proposed that the
change in phosphate concentration is responsible for shifting
the fluoride dose response. This study used chick calvaria
cells and the means of six replicates and standard deviations
are given (unpublished data from K.-H.W. Lau of Loma Linda
University, Loma Linda, CA.)
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3) Fluoride Induced Osteoblast Proliferation is
Dependent on the Presence of Growth Factors
Osteoblasts produce and respond to a number of growth factors both
in vivo and in vitro [46].

Thus, when monolayers of osteoblasts

are grown for several hours in unsupplemented (serum free) medium,
detectable levels of certain growth factors can be measured (IGF-I,
IGF-II etc) (the medium is then referred to as conditioned medium, not
serum free medium).

Fluoride induced osteoblast proliferation has

been shown to be dependent on the presence of factors in conditioned
medium [22].

This conclusion was based on the fact that fluoride was

mitogenic for osteoblasts when added to cells growing in conditioned
medium, whereas fluoride had no effect on osteoblast proliferation
when added to cells along with fresh serum free medium [22].
Additionally, fluoride’s ability to stimulate osteoblast mitogenesis
was restored in fresh serum free medium when growth factors were added
to the cells along with fluoride (IGF-I, insulin) [22].

Therefore,

fluoride appears to induce osteoblast proliferation by increasing the
effectiveness of endogenous growth factors, not by directly initiating
DNA synthesis [22].

4) Tissue Specificity of Fluoride Induced Cell
Proliferation
Fluoride’s ability to induce cell proliferation appears to be
tissue specific.

Previous in vitro studies have shown that fluoride

could stimulate proliferation in monolayer cultures of bone cells, but
not in parallel cultures of cells prepared from skin, muscle, liver,
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intestine or kidney [23].

On the other hand, a study by a Japanese

group showed that fluoride was mitogenic for Green monkey kidney cells
[47].

Because of the apparent cell/tissue specificity of the

mitogenic effects of fluoride, it can be speculated that the mechanism
by which fluoride stimulates cell proliferation might be unique to
bone cells (and perhaps also kidney cells).

5) Fluoride-Dependent Osteoblast Differentiation
Mitogenic concentrations of fluoride not only stimulate
proliferation of osteoblasts, but also increase osteoblastic
differentiation.

For example, fluoride, at mitogenic doses, has been

shown to increase alkaline phosphatase specific activity [23,24],
collagen production [23] and osteocalcin synthesis [48]. (Osteoblastic
alkaline phosphatase activity is an indicator of osteoblastic
differentiation, as differentiated osteoblasts contain more alkaline
phosphatase activity than do osteoblast progenitor cells [23].)

It is

intriguing that mitogenic concentrations of fluoride increase both the
proliferation and differentiation of osteoblasts, since it is well
known that proliferating cells do not differentiate, and that
differentiating cells do not proliferate.

However, because the cells

used in those studies are mostly of mixed cell populations, it is
possible that fluoride can have differential effects on different cell
subpopulations.

In this regard, previous studies have shown that

fluoride acts primarily to stimulate proliferation of less
differentiated bone cells [49].

Nevertheless, it is clear that

fluoride has both proliferative and differentiative effects on

11
osteoblasts.

This dissertation will focus on the proliferative

effects of fluoride.

6) Cellular Responses to Micromolar Fluoride
Concentrations
Since the proliferative response to fluoride occurs at fluoride
concentrations in the micromolar range, it seems reasonable to assume
that the biochemical events responsible for fluoride-induced cell
proliferation are also occurring at these low concentrations.
Therefore, a brief discussion about the dose-dependent effects of
fluoride on cellular processes and enzymes and their potential
relationship with fluoride induced cell proliferation is warranted
(fluoride induced effects which are only elicited with concentrations
in the millimolar range will not be discussed, including, fluoride’s
ability to inhibit serine/threonine phosphatases [40] and to activate
adenylate cyclase [50]).

a) Phosphate Transport
Fluoride has been shown to activate sodium-dependent phosphate
transport in osteoblast-like cells in a dose-dependent manner [51,52].
In these experiments, it was shown that fluoride enhanced submaximal
IGF-I induced phosphate transport while not affecting the maximal
response to IGF-I [51,52].

It was concluded that fluoride may have

acted via a mechanism similar to that of IGF-I to stimulate phosphate
transport.
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The significance of increased phosphate uptake with respect to
cell proliferation is unclear.

In this regard, previous studies have

suggested that addition of phosphate to cells would increase cell
proliferation in vitro [53], implying that increased phosphate uptake
may be involved in the mitogenic mechanism of fluoride.

On the other

hand, it should be noted that the activation of sodium-dependent
phosphate transport occurred with doses of fluoride ranging form IOOuM
to ImM, which are at least one order of magnitude higher than the
mitogenic doses.

In fact, ImM fluoride, under most circumstances,

inhibits osteoblast proliferation.

Therefore, the discrepancy between

the dose-dependency of fluoride induced cell proliferation and of
fluoride induced sodium-dependent phosphate transport does not support
the premise that activation of phosphate transport in osteoblasts is
responsible for mediating fluoride induced osteoblast proliferation.

b) ATPase Activities
Fluoride was shown to affect several ion transporting ATPase
activities in monolayer bone cell cultures grown in Medium 199
(Earle’s salts, ImM phosphate) [34].
Fluoride concentrations of IpM and 5pM, but not lOpM, increased
HCOg-ATPase activity.

The HCOg-ATPase is believed to be a

mitochondrial enzyme [34], and the relationship of this mitochondrial
enzyme activity with cell proliferation is unclear at the present
time.
A fluoride concentration of lOpM was shown to increase Na+,K+ATPase activity [34], an enzyme which functions to exchange
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intracellular sodium with extracellular potassium.

Fluoride’s effect

on the activity of the Na+,K+-ATPase is interesting, since it was
shown that Na+,K+-ATPase activity correlated with mitogenesis in
cultured human retinal pigment epithelial cells [54].

However, since

fluoride is not mitogenic for epithelial cells, fluoride’s ability to
increase Na+,K+-ATPase activity may not be related to fluoride’s
ability to stimulate osteoblast proliferation.
Finally, IOjiM fluoride decreased the activity of the Ca++ ,Mg++ATPase [34].

Ca++,Mg++-ATPase functions to remove cytoplasmic calcium

and an inhibition of this enzyme could result in an increase in
cytoplasmic calcium concentrations.

The relationship between the

Ca++,Mg++-ATPase activity and cell proliferation is unclear, however,
since thapsigargin, an inhibitor of this enzyme activity [55], has
been shown to increase mouse epidermal cell proliferation in vivo
[56], inhibit HEL30 keratinocyte proliferation in vitro [56], inhibit
DDT.jMF-2 smooth muscle cell proliferation [57], and have no effect on
human lymphocyte proliferation [58].
It should also be noted that the studies of these ATPase
activities were performed in confluent cultures, a condition which is
not optimal for fluoride induced mitogenesis, since osteoblasts lose
their mitogenic responsiveness to fluoride at high cell densities
[25].

Furthermore, the studies were carried out using medium with a

phosphate concentration of ImM, and most of the changes in ATPase
activity occurred with fluoride doses around 10|iM.

With a phosphate

concentration of only ImM, 10|iM fluoride would not be expected to be
mitogenic (see Figure 1 pg. 7), and so the changes in activities of
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these ATPase activities at 10|iM fluoride were probably not related
with fluoride induced osteoblast proliferation.

While it is not yet

clear whether fluoride’s effect on these ATPase activities is involved
in the halogen’s mitogenic action, the aforementioned evidence is not
consistent with this possibility.

c) Calcium
Fluoride induced increases in calcium uptake in a biphasic dosedependent manner (osteoblasts cultured in BCJ^ medium) [33].
Increases in fluoride-dependent calcium uptake occurred with doses
ranging from 20pM to 200pM, which are within the range of fluoride
doses that stimulate osteoblast proliferation (20pM fluoride was
mitogenic for the cells used in these experiments).

Furthermore,

verapamil, a calcium channel blocker, was shown to prevent fluoride
induced calcium uptake and bone cell proliferation [33].

These data

are consistent with the possibility that calcium flux into osteoblasts
may mediate fluoride induced osteoblast proliferation.

However,

because the potential involvement of calcium in the mitogenic action
of fluoride is beyond the scope of this dissertation, the issue as to
whether fluoride stimulates bone cell proliferation by activating
calcium mobilization will not be further addressed.

d) Acid Phosphatases
Acid phosphatases (ACPs) are enzymes which optimally
dephosphorylate phosphoester bonds in acidic medium.

It is now clear

that there are at least two classes of ACPs, lysosomal and
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nonlysosomal.

While lysosomal ACPs are thought to hydrolyze phosphate

bonds in the lysosomes [59], the physiologic significance of
nonlysosomal ACPs has not been clearly defined.
Osteoblastic ACP activities have been shown to be inhibited by
micromolar concentrations of fluoride (see Table 1, pg. 5) [29,35,44].
Previous studies indicated that the apparent inhibition constant for
fluoride of this enzyme was similar to the apparent activation
constant for fluoride to stimulate bone cell proliferation [29],
suggesting that the inhibition of this enzyme activity might be
associated with the activation of osteoblast cell proliferation.

The

relationship between the osteoblastic fluoride-sensitive ACPs and
fluoride induced proliferation of bone cells appears to be
particularly relevant when one compares the tissue distribution of the
fluoride-sensitive ACPs with the tissues which respond mitogenically
to fluoride (a fluoride sensitive ACP is defined here as having a K i
less than lOOpM). As discussed above (pg. 9), the mitogenic response
to fluoride appears to be unique to bone and kidney cells.

The

sensitivity to inhibition to mitogenic concentrations of fluoride
appears also to be specific for ACPs derived from bone and kidney
cells.

These coincidences provide circumstantial evidence for the

potential involvement of this ACP in the biochemical mechanism
mediating the mitogenic action of fluoride.
The correlation between the tissue specificities of fluoridesensitive ACP and fluoride induced cell proliferation has been, until
very recently, difficult to explain biochemically.

Part of this

difficulty arose because ACPs were generally assumed to be of
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lysosomal origin (and therefore only functioning in lysosomal
degradation pathways).

This dogma has now been challenged by the

characterization of cytoplasmic ACPs [60-62].

In this regard,

osteoblastic ACPs have been shown to be of nonlysosomal origin [63].
The physiologic function of these nonlysosomal ACPs is not known.
However, recent evidence suggests that some, if not all, non-lysosomal
ACPs could act as phosphotyrosyl protein phosphatases (PTPPs) under
physiologically relevant conditions [29,35,36,64-66].

These ACPs

resemble the PTPPs in that they are sulfhydryl-dependent enzymes.

On

the other hand, the ACPs which have been sequenced do not possess
sequence homology with the catalytic domain of the PTPPs which have
been previously purified and sequenced [67].

Therefore, ACP-like

PTPPs could represent a new class of PTPP enzymes [68].
The fluoride-sensitive ACPs which have been identified in bovine
bone and human osteoblasts have also been shown to possess fluoridesensitive PTPP activity [29,35].

It is not known at the present time

whether or not the osteoblastic ACP/PTPP shares sequence homology with
members of the multigene family of PTPPs.

Because PTPP activities

potentially play a major regulatory role in cell proliferation and
differentiation, it was conceivable that the mitogenic effects of
fluoride could be mediated by a specific inhibition of this
osteoblastic ACP/PTPP activity, such that it would increase the steady
state tyrosyl protein phosphorylation levels in bone cells.
theme of this dissertation is to test this hypothesis.

The major
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e) Effect of Fluoride on Tyrosyl Phosphorylation
There is evidence to support the contention that mitogenic doses
of fluoride increase the steady state level of phosphotyrosyl proteins
in chicken bone cells [29].

This is important because it supports the

concept that fluoride affects cellular phosphotyrosyl phosphorylation.
Increases in steady state levels of tyrosyl phosphorylation could be
achieved by either activating tyrosyl protein kinase activities or by
inhibiting PTPP activities, or both.

However, it has been shown that

mitogenic concentrations of fluoride had no effects on protein
thiophosphorylation.

[Protein thiophosphorylation is the process

which occurs when kinase activities transfer thiophosphate from ATPgamma-S to their protein substrates.

Thiophosphorylated proteins have

been shown to be poor substrates for both phosphoseryl/phosphothreonyl
protein phosphatases and phosphotyrosyl protein phosphatases [69,70].
Thus, any change in the level of thiophosphorylation in this system
can be attributed to changes in kinase activity [29].

These findings

are consistent with the interpretation that fluoride influenced net
tyrosyl protein phosphorylation not by activation of tyrosyl kinase
activities, but rather by inhibition of the dephosphorylation process
[29].

IV.

Tyrosyl Phosphorylation

Before the significance of fluoride inhibiting a PTPP activity
will be discussed, it seems appropriate to discuss the physiologic
importance of cellular tyrosyl phosphorylation in general.
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Phosphorylated tyrosyl residues normally account for 0.01-0.05% of
the total protein phosphoamino acid content [71], however, this value
may increase up to 3% when cells are infected with some types of
viruses [71,72].

Because tyrosyl phosphorylation makes up such a

small portion of the total amount of cellular protein phosphorylation,
it remained undetected until the late 1970’s and early 1980’s [71,73].
Since its discovery, it has become increasingly clear that tyrosyl
phosphorylation is an extremely important cellular regulatory event
and a major signal transduction mechanism for cell proliferation and
differentiation.
Several lines of evidence indicate that tyrosyl protein
phosphorylation is closely associated with the regulation of cell
proliferation, differentiation and transformation [74-76].

The fact

that many polypeptide growth factor receptors contain intrinsic
tyrosyl kinase activities that become activated when their respective
growth factors are bound, supported a role for tyrosyl phosphorylation
in mediating growth factor induced cell proliferation [77-83].

This

reasoning was further supported by experiments involving site directed
mutagenesis.

Point mutations which abolished the tyrosyl kinase

catalytic domains of polypeptide growth factor receptors inhibited the
ability of the receptors to mediate the proliferative responses
induced by their effector binding [84-87].

Beyond polypeptide growth

factor receptors, several oncogene products possess tyrosyl kinase
activities which are essential for the biologic actions of the
transforming proteins [88].

Tyrosyl phosphorylation has also been

shown to play a central role in regulating the timing and onset of
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mitosis and in the order of cell cycle events [89].

Finally, tyrosyl

phosphorylation acts as a switch to induce binding of Src homology 2
domains, thus mediating complex formation of several cytoplasmic
signaling proteins [90].

Therefore, it is now clear that tyrosyl

phosphorylation of key cellular proteins is an important pathway for
regulating and stimulating cell proliferation.

The following sections

will briefly describe the enzyme activities that regulate the level of
tyrosyl phosphorylation in cells.

1) Tyrosyl Protein Kinases
The steady state level of tyrosyl phosphorylation is regulated by
the balance of the tyrosyl protein kinase and PTPP activities.
Tyrosyl protein kinases are the enzymes that catalyze the transfer of
phosphate from ATP to protein tyrosine residues [91].
The tyrosyl kinases can be separated into two classes; receptors
and non-receptors [92].

The receptor tyrosyl kinases are further

divided into four subclasses based on unique structural subdomains
(Figure 2).

Subclass I receptor tyrosyl protein kinases are monomeric

receptors which contain two cysteine-rich sequence repeats in their
extracellular domains [86].
receptor.

A member of this subclass is the EGF

Subclass II receptor tyrosyl protein kinases are

heterotetrameric receptors made up of two alpha and two beta subunits.
The subunits are connected by disulfide linkages, with the alpha
subunits making up the ligand binding region and the transmembrane
beta subunits containing the tyrosyl protein kinase catalytic regions
[86].

The receptors for IGF-I and insulin are examples of this
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Figure 2. Different subclasses of receptor tyrosyl kinases.
See text for details.
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subclass.

Subclass III receptor tyrosyl protein kinases (e.g. PDGF

receptor) are monomeric receptors which lack extracellular cysteinerich repeat regions.

Subclass III is additionally unique in that it

contains a hydrophilic region which disrupts the catalytic domain
[86].

Subclass IV tyrosyl kinase receptors are dimeric receptors in

which both subunits contribute to the ligand binding region but only
one spans the membrane and contains tyrosyl protein kinase activity
[93].

A known member of this subclass is the MET proto-oncogene.
The receptor tyrosyl protein kinase activities are generally

active only in response to ligand binding [94].

This makes

teleological sense because the phosphorylation event consumes a high
energy phosphate bond which would be wasted in a futile cycle.
The non-receptor tyrosine kinases are generally smaller than the
receptor tyrosyl protein kinases [95], they share extensive sequence
homology near their carboxy terminus [95], they lack large hydrophobic
regions which could span the plasma membrane [95], and they include
many proto-oncogene products [92].

The non-receptor tyrosine kinases

are typified by p60 src [91], a 60kD soluble tyrosyl protein kinase
which is phosphorylated by the EGF receptor and has been shown to be
capable of transforming cells [95,96].

Presently, the src, abl and

fps/fes gene families are known to code for and express non-receptor
tyrosyl protein kinases [97], and this list will undoubtedly continue
to grow as investigations continue into the nature of these important
enzymes.
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2) Phosphotyrosyl Protein Phosphatases
There is a large multi gene family of PTPPs in mammalian and nonmammalian cel Is.

This family of enzymes, with the exception of those

found in bacteria and viruses [68], is highly specific for the
phosphotyrosine moiety, with no appreciable activity toward
phosphoserine or phosphothreonine residues.

In addition, the members

of this family of enzymes all contain one or two domains which share a
high degree of sequence homology.

This domain (shown as the cytosolic

shaded boxes in Figures 3 {pg. 24} and 4 {pg. 27}) is known as the
"catalytic domain".
PTPPs can generally be classified as being either cytosolic or
transmembrane enzymes [68,73 98].

The cytosolic PTPPs can be further

divided into enzymes with either C-terminal or N-terminal extensions
to the catalytic domain (Figure 3) [68].
The cytosolic PTPPs which contain C-terminal extensions can be
subclassed based on the characteristics of those extensions.

The

first subclass contains a C-terminal domain which is inhibitory [99].
The enzymes of this subclass are synthesized as inactive proenzymes
[100,101] which must have part of their C-terminal extension removed
before being fully active [99,102].

The second subclass contains a C-

terminal region which shows a high degree of homology to the
transcription factors Fos and Jun [103], which may target the enzymes
to act in the nucleus.

The third and final subclass contains PEST

sequences in their C-terminal extension [104].

PEST sequences are

those which contain an increased amount of proline (P), glutamic acid
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Figure 3. Schematic representation of the cytosolic
phosphotyrosyl protein phosphatases. See text for details
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(E), serine (S) and threonine (T).

These sequences have been shown to

predispose proteins to rapid degradation [105].
The cytosolic PTPPs which contain N-terminal extensions can also
be further subclassed based on the properties of these unique regions.
The first subclass contains a long N-terminal region whose function
remains unclear.

At the present time, this subclass has not been

found in mammals [68].

The second subclass has an N-terminal

extension containing two Src homology region 2 domains [106-108].

Src

homology region 2 is a noncatalytic domain found on several
cytoplasmic signaling proteins which binds to phosphorylated tyrosyl
residues [109].

Tyrosyl phosphorylation acts as a switch to induce

binding of Src homology 2 domains, thus mediating complex formation
[90,109].

The third subclass contains a myristylation site within

their N-terminal region.
to bind to membranes.

This modification could allow these enzymes

The fourth subclass contains regions at the

N-terminus which appear capable of binding to cytoskeletal proteins
[110,111].
The transmembrane PTPPs were divided into four classes based on
properties unique to the enzymes (Figure 4).

Class 1, the receptor

like class, was so named because these enzymes have extracellular
domains with traits similar to those of ligand binding receptors
[112].

The two intracellular catalytic domains of class 1

phosphatases have been shown to have different substrate specificities
[113].

Class 2 transmembrane PTPPs also have two intracellular

catalytic domains.

However, this class differs from class 1 in that

the extracellular region contains several repeated fibronectin type
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Figure 4. Schematic representation of the transmembrane
phosphotyrosy! protein phosphatases. See text for details.
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Ill-like and immunoglobulin-like sequences [114,115].

Class 3

transmembrane PTPPs also have two intracellular catalytic domains,
however, this class has a very short extracellular domain which has no
sequence homology to any known proteins [116].

Class 4 transmembrane

PTPPs contain extracellular fibronectin type Ill-like repeats,
however, this class is unique from all the others in that it contains
only one intracellular catalytic domain [116].

The structures of

these enzymes suggest that classes 1, 2 and 4 may be able to act as
cell surface receptor-like macromolecules, however, no ligands for
these "putative" receptors have been identified.
In addition to this large multigene family of PTPPs, several other
enzymes have been shown to dephosphorylate phosphotyrosyl proteins in
vitro.

These enzymes include i) Type 2B, calcium and calmodulin

dependent protein phosphatases [117], ii) alkaline phosphatases
[118,119] and nonlysosomal acid phosphatases [65,66].

Kinetic

evaluations indicate that the PTPP activities of the type 2B protein
phosphatases and the alkaline phosphatases are probably not
physiologically important [73].

On the other hand, the kinetic

properties of the nonlysosomal ACP/PTPPs are consistent with being
physiologically relevant [73].

The facts that the protein phosphatase

activities of these nonlysosomal ACPs is specific for phosphotyrosyl
proteins [73], and that the PTPP activity of these ACPs exhibited
neutral pH optima [73], are also consistent with the possibility that
the nonlysosomal ACPs could function physiologically as PTPP
activities in cells.
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3) Role of Phosphotyrosy! Protein Phosphatases
While it has been known that cellular levels of tyrosyl
phosphorylation are maintained by a balance of tyrosyl protein kinase
and PTPP activities, it has been generally assumed that the tyrosyl
protein phosphorylation reaction is the key regulatory process in the
tyrosyl protein phosphorylation system [73].

The dephosphorylation

reaction catalyzed by the PTPPs has often been thought of as an
unregulated cellular event [120].

However, there is now a body of

evidence supporting a regulatory role for PTPP activities.
In support of a regulatory role for PTPP activities, it has been
shown that there can be coordinated changes in both tyrosyl protein
kinase and PTPP activities.

Transformation of chicken fibroblasts by

Rous sarcoma viruses [121], nonmalignant hyperplastic cell growth in
psoriatic skin [122] and differentiation of HL-60 human leukemia cells
[123] have all been shown to result in increases in both tyrosyl
protein kinase and PTPP activities.
The identification and characterization of two cellular heatstable protein inhibitors [124] and an activator [125] of PTPP
activities suggested that the phosphatase activities are subjected to
cellular regulatory controls.

Furthermore, a PTPP containing two Src

homology domains was identified which binds to autophosphorylated EGF
and PDGF receptors and is itself activated by tyrosyl phosphorylation
[126-128].

This demonstrates that PTPPs do not have passive roles in

the regulation of tyrosyl phosphorylation, and that the tyrosyl
protein kinases and PTPPs could both actively regulate each other’s
functions [68,73].
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There is additional evidence that PTPPs may play a major role in
regulating the cellular events controlled by tyrosyl phosphorylation.
i) Microinjection of a purified PTPP into oocytes inhibited the action
of insulin [129], and retarded the insulin induced maturation [130].
ii) A membrane associated PTPP has been shown to have elevated
activity in contact inhibited fibroblasts [131].

iii) Heat shock

induced tyrosyl phosphorylation was associated with an inhibition of a
PTPP activity [132].

iv) Binding of somatostatin or its analogs to

its cell surface receptor has been shown to activate a membrane
associated PTPP activity through a G-protein [133].

The activation of

this PTPP activity correlated with the anti-cancer growth ability of
somatostatin [134,135].

And v) expression of a transmembrane PTPP

activity in murine C127 cells inhibited mitogenic responses to PDGF
and IGF-I [136].

These observations, in aggregate, indicate that PTPP

activities are important determining factors of cellular protein
phosphotyrosine levels and cellular functions.

V.

Proposed Mechanism for Fluoride Induced

Osteogenesis
A model has been proposed to explain mitogenic action of fluoride
in osteoblasts.

This model was developed based on the following

findings: a) Micromolar concentrations of fluoride increased net
tyrosyl phosphorylation in osteoblast membrane preparations [29].

b)

Fluoride had no effect on the rate of protein thiophosphorylation in
osteoblast cell extracts [29].

c) An osteoblastic AGP with

physiologically relevant PTPP activity was found to be inhibited by
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micromolar concentrations of fluoride [35].

d) Other inhibitors (e.g.

vanadate and molybdate) of the osteoblastic ACP/PTPP activity induced
osteoblast proliferation with the same concentrations [29].

e) The

osteogenic capacities of fluoride, orthovanadate and molybdate
required the presence of tyrosyl protein kinase activating growth
factors (further supporting PTPP inhibition rather than tyrosyl
protein kinase activation as the means for increasing tyrosyl
phosphorylation because tyrosyl protein kinase activators were also
required) [29].

And f) genistein, a tyrosyl protein kinase inhibitor,

completely abolished the mitogenic action of fluoride [28], indicating
that tyrosyl phosphorylation is an important mediator of fluoride
induced mitogenesis.

[This observation that a tyrosyl protein kinase

inhibitor abrogated fluoride induced mitogenesis is consistent with
fluoride induced proliferation requiring a tyrosyl protein kinase
activator, and does not alter the concept of fluoride acting via PTPP
inhibition.]
In this model (Figure 5), the binding of a growth factor to the
extracellular domain of its cell surface receptor activates the
intrinsic tyrosyl protein kinase activity in the intracellular domain
of the receptor.

The activation of tyrosyl protein kinase activity

would then lead to increased tyrosyl phosphorylation of specific
cellular proteins, which are believed to mediate the mitogenic
pathway.

[These cellular phosphotyrosyl proteins are termed

"mitogenic signaling proteins" in this dissertation.]

The tyrosyl

phosphorylation of the mitogenic signaling proteins eventually leads
tq increased cell proliferation.

Under normal circumstances, cellular
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Figure 5. Proposed molecular mechanism for fluoride induced
osteoblast-like cell proliferation. It is proposed that fluoride
stimulates osteoblast-like cell proliferation by specifically
inhibiting a phosphotyrosy! protein phosphatase, resulting in
increased cellular steady state levels of tyrosyl
phosphorylation of key mitogenic signaling proteins.
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PTPPs catalyze the dephosphorylation of the mitogenic signaling
proteins, and thus, the mitogenic signal is subsequently terminated.
It is proposed that fluoride acts as a specific inhibitor of certain
key cellular PTPPs to abolish their activity.

As a result, the

dephosphorylation of the mitogenic signaling proteins is prevented and
the mitogenic signal is prolonged.

In this regard, fluoride can be

considered as a mitogen enhancer rather than a mitogen per se.

This

speculation is consistent with the observations that the mitogenic
action of fluoride requires the presence of growth factors [22] and is
inhibited by tyrosyl protein kinase inhibition [28].
This model, if correct, should predict that fluoride treatment
will result in dose- and time-dependent changes in the steady state
level of tyrosyl phosphorylation of specific cellular proteins, and
the phosphorylation level of at least some of these phosphotyrosyl
proteins should correlate with fluoride induced mitogenesis.

VI.

Other Bone Cell Mitogens
One of the goals of this dissertation was to correlate fluoride

induced changes in tyrosyl phosphorylation with cell proliferation,
and it was felt that changes in tyrosyl phosphorylation induced by
other bone cell mitogens could provide clues as to which proteins are
the key mitogenic signaling proteins for osteoblasts.

It was reasoned

that if the proliferative response to fluoride is dependent on
increasing steady state levels of tyrosyl phosphorylation, other bone
cell mitogens should increase the steady state levels of tyrosyl
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phosphorylation of similar proteins.

Accordingly, my approach was to

determine the effects of other bone cell mitogens on cellular tyrosyl
phosphorylation in human bone cells and compare them to fluoride
dependent changes in tyrosyl phosphorylation.

In this dissertation,

four classes of bone cell mitogens were tested (in addition to
fluoride).

These were: a) agents that inhibit PTPP activity, e.g.

vanadate; b) polypeptide growth factors whose receptors are tyrosyl
kinases, e.g. IGF-I, PDGF and EGF; c) polypeptide growth factors whose
receptors are not tyrosyl kinases, e.g. IGF-II; and d) electromagnetic
fields, whose relationship to tyrosyl protein phosphorylation is
unknown.

The following discussion will briefly examine these

mitogens.

1) Sodium Orthovanadate
In mouse lens cells, concentrations of vanadate which increased
DNA synthesis also increased tyrosyl phosphorylation [137].

Vanadate

has been shown to be a specific inhibitor of most phosphotyrosyl
protein phosphatase activities [138-141], and it is generally thought
that these inhibitions are principally responsible for vanadate
induced increases in cellular levels of tyrosyl phosphorylation [138141].

However, it should be noted that strong inhibition of

phosphotyrosyl protein phosphatases by vanadate is not universal
[141], and vanadate has also been shown to be capable of directly
activating the tyrosyl kinase activity of the insulin receptor [141].
Vanadate, like fluoride, has been shown to be a potent inhibitor
of osteoblastic ACP/PTPP [29,142].

Since we have hypothesized that
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fluoride induces osteoblast proliferation by inhibiting the
osteoblastic ACP/PTPP activity, the effects of vanadate on tyrosyl
phosphorylation are expected to be similar to those induced by
fluoride, if the hypothesis is correct.

On the other hand, it should

also be remembered that vanadate is a more potent and broader ranged
inhibitor of PTPP than fluoride and that vanadate might also stimulate
tyrosyl protein kinase activities.

Thus, the changes in tyrosyl

phosphorylation induced by vanadate may not be identical to the
changes in tyrosyl phosphorylation induced by fluoride.

2) Insulin-like Growth Factor I
IGF-I has a molecular weight of 7.6 kD and it has been shown to
stimulate human bone cell proliferation in a dose-dependent manner
[143].

The IGF-I receptor (450kD [143]) is a subclass II receptor

tyrosyl kinase [86] (please see Figure 2, pg. 20) with a
heterotetrameric structure consisting of 2 alpha and 2 beta subunits
[46].

The beta subunits (96kD) undergo autophosphorylation when

activated by IGF-I, and when cells treated with IGF-I are
electrophoresed on reducing polyacrylamide gels, immediate increases
in tyrosyl phosphorylation are observed in a 96kD protein band [81].
It is generally believed that IGF-I induced cell proliferation is
mediated by tyrosyl phosphorylation induced by its receptor tyrosyl
protein kinase activity [46].
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3) Platelet Derived Growth Factor
PDGF is a potent mitogen for cells of mesenchymal origin,
including osteoblasts [144-146].

PDGF is a relatively large

polypeptide growth factor, with an apparent molecular weight of 32 kD
[143], and the PDGF receptor is a subclass III tyrosyl protein kinase
receptor [86] (please see Figure 2, pg. 20) with an apparent molecular
weight of 180 kD [147].

The tyrosyl protein kinase activity of the

PDGF receptor is an essential mediator of PDGF induced cell
proliferation [83].

Therefore, it is speculated that at least some of

the proteins which are tyrosyl phosphorylated in response to PDGF must
be related with PDGF-induced osteoblast proliferation.

4) Epidermal Growth Factor
EGF is another polypeptide growth factor which stimulates
osteoblast-like cell proliferation [144,148,149].

EGF is a 6kD

protein [150] and its receptor is an autophosphorylating subclass I
receptor tyrosyl kinase [86] (please see Figure 2, pg. 20) with an
apparent molecular weight of 170kD [87].

EGF induced cell

proliferation has been shown to be entirely dependent on the tyrosyl
kinase activity of its receptor [86,87].

Therefore, at least some of

the proteins which are tyrosyl phosphorylated in response to EGF
treatment can be speculated to be key mitogenic signaling proteins.

5) Insulin-like Growth Factor II
IGF-II (7.5kD [150]) is the most abundant growth factor found in
human bone matrix [46,143], and human bone cells synthesize and
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secrete more IGF-II than any other growth factor [143].

The IGF-II

receptor exhibits no disulfide linkages and has a molecular weight of
approximately 250kD [151-153], and unlike the IGF-I receptor, the IGFII receptor does not contain intrinsic tyrosyl kinase activity [143].
However, the IGF-II receptor has been shown to be phosphorylated on
tyrosyl residues [153], and so even though the IGF-II receptor has no
intrinsic tyrosyl protein kinase activity, tyrosyl phosphorylation
could still play a role in mediating cellular responses to IGF-II.
Presently, it is unclear whether or not the IGF-II receptor
mediates IGF-II induced cell proliferation.
IGF-II can bind to the IGF-I receptor,

It has been shown that

and some investigators believe

that IGF-II induced cell proliferation is mediated through the IGF-I
receptor tyrosyl protein kinase [46].

However, experiments in

osteoblasts in which the IGF-II receptor was blocked by neutralizing
antibodies showed that the IGF-II receptor is probably involved in
mediating IGF-II induced osteoblast proliferation [46].

This

dissertation may aid in identifying the receptor which mediates IGF-II
induced osteoblast proliferation, since changes in tyrosyl
phosphorylation induced by IGF-II should be the same as those induced
by IGF-I if IGF-II is acting through the IGF-I receptor (on the other
hand, if the tyrosyl phosphorylation patterns are markedly different
between IGF-II and IGF-I, that would be suggestive that IGF-II is not
activating the IGF-I receptor, but rather that IGF-II is inducing
tyrosyl phosphorylation by activating some other tyrosyl protein
kinase activity).
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6) Electromagnetic Fields
Stress generated potentials are created when bone undergoes
mechanical loading [154,155], and it has been suggested that bone
remodeling may, in part, be regulated by these potentials [154,155].
It has been proposed that externally applied low level electromagnetic
fields may resemble many aspects of the streaming potentials induced
by mechanical loading.

In this regard, electrical stimulation has

been shown to aid in the healing of non-union fractures [156].
Furthermore, electromagnetic field exposure has been consistently
shown to stimulate osteoblast-like cell proliferation in vitro
[154,155,157].

The mechanism by which electromagnetic fields induce

osteoblast mitogenesis is not well understood.

Recent evidence

suggests that IGF-II release and calcium uptake may be involved in
mediating electromagnetic field induced osteoblast proliferation
[155].

It has not yet been determined whether or not electromagnetic

fields can alter cellular levels of tyrosyl phosphorylation. This
study will, therefore, contribute to our understanding of how
electromagnetic fields affect osteoblasts with respect to tyrosyl
protein phosphorylation.

VII.

Method Selection:
To evaluate the effects of bone cell mitogens on steady state

levels of tyrosyl phosphorylation, a sensitive and reliable method is
required.

At the present time there are three basic methods for

assessing the phosphotyrosyl protein content in cells.
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The first method is based on the concept that phosphotyrosine is
much more stable than phosphoserine or phosphothreonine under alkaline
conditions [158].

Accordingly, phosphotyrosyl proteins can be

detected after the [32P] labeled phosphoproteins are subjected to
1 hour of treatment with 1M potassium hydroxide.

The alkaline stable

[32P] counts would more or less correspond to the phosphotyrosyl
protein content.

This method only crudely approximates total cellular

tyrosyl phosphorylation.
The second method involves labeling the phosphorylation events
with [32P] ATP, separating the proteins by gel electrophoresis and
then identifying the type of phosphorylation by hydrolyzing excised
proteins with 6M hydrochloric acid.

The hydrolyzed phosphoamino acids

are then separated by thin layer electrophoresis [159].

Since

phosphoserine, phosphothreonine and phosphotyrosine migrate
differently on thin layer electrophoresis, the type of phosphorylation
can be assessed by comparing the location of the individual dots with
standards.

One major advantage to this method is that the effects on

all types of phosphorylation can be assessed in the same experiment.
The drawbacks are that: a) the method requires extensive handling of
the strong p-emitter, [32P]; b) the number of comparisons within an
experiment is limited by the ability to excise the proteins from the
gels.

And c) the results would provide mostly a qualitative rather

than a quantitative evaluation.
The third method involves the use of specific antibodies against
phosphotyrosine.

Immunodetection of tyrosyl phosphorylated proteins

involves treating cells with effectors and separating the cellular
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proteins by SDS-PAGE as above.

However, the cells are not

radioisotopically labeled, and so it is much easier and safer to
handle the cell extracts and gels.

Following PAGE, the proteins are

transblotted onto nitrocellulose membranes where the phosphotyrosyl
proteins are identified by anti-phosphotyrosine antibodies [92].
(Specific anti-phosphotyrosine antibodies are now commercially
available.)

The proteins are then visualized by an alkaline

phosphatase conjugate, enhanced chemiluminescence or by radiolabeled
protein A.

While this method can also use radioisotopes, they are

only used in the last step and so sample handling is much easier and
safer.

Autoradiograms can be made by the enhanced chemiluminescence

and protein A methods and the amount of phosphorylation can be
quantitated by laser densitometry.
The immunodetection technique was chosen for these studies because
of its relative safety, and its sensitivity for quantitative
measurements of phosphotyrosyl proteins.

CHAPTER TWO
MATERIALS and METHODS

I.

Materials:
All reagents were of electrophoresis grade or better.

Dulbecco’s

Modified Eagle Media (DMEM), bovine calf serum,
penici11 in/streptomycin/amphotericin B antibiotic/antimycotic and
trypsin were obtained from Gibco (Gaithersburg, MD).

Bovine serum

albumin (fraction V, RIA grade) was purchased from United States
Biochemical Corp. (Cleveland, OH).

Glycine, Iris, 2-mercaptoethanol,

sodium dodecyl sulfate (SDS), N.N.NlN’-tetramethyl-ethylenediamine
(TEMED), polyoxyethylene sorbitan monolaurate (TWEEN 20), sodium
hydroxide, sodium azide, sodium chloride, Folin-Ciocalteu’s phenol
reagent and dimethyl sulfoxide (DMSO) were obtained from Sigma (St
Louis, MO).

Protein A and Protein G were from Fluka Chemical Corp.

(Ronkonkoma, NY).

Monoclonal antiphosphotyrosine antibodies PY20 and

PY69, ammonium persulfate, sodium orthovanadate and bromophenol blue
were obtained from ICN (Costa Mesa, CA).

X-ray film (RX medical x-ray

film) was purchased from Fuji Photo Film Co. Ltd. through local
suppliers.

Tissue culture plates and sterile disposable test tubes

were obtained from Corning Inc. (Corning, NY).

3-27% gradient

polyacrylamide gels (gels) were purchased from either First Page
(Hudson, OH) or Jule Biotechnologies (New Haven, CT).

Supported

nitrocellulose membranes with a pore size of 0.22 microns were
obtained from Intermountain (Bountiful, UT) and MSI (Westboro, MA).
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Methanol and Whatman filter paper (185g/m2, 0.33mm thick, medium flow
rate) were purchased from Fisher (Los Angeles, CA).

Recombinant

human PDGF, IGF I and EGF were obtained from Austral Biologicals (San
Ramon, CA).

Recombinant IGF-II was obtained from BACHEM Bioscience

Inc. (Philadelphia, PA).

Sodium fluoride was purchased from Spectrum

Chemical Mfg. Corp. (Gardena, CA).

Absolute ethanol was purchased

from Midwest Grain Products of Illinois (Pekin, IL).

Prestained PAGE

standards were obtained from Bio-Rad (Hercules, CA).

II.

Cell Culture

Normal human bone samples were obtained from healthy patients during
elective surgery and the cells were released from the bone chips by
collagenase treatment according to Wergedal et al [160].

The normal

bone cells used were of mandibular, rib and bone marrow origins and
the cells were stored frozen in liquid nitrogen as described below.
Prior to being used for these experiments, the cells were shown to be
osteoblast-like based on the following; 1) osteocalcin production and
secretion in response to 1,25(0H)2D3, 2) alkaline phosphatase
activity, and 3) increased cellular cAMP in response to parathyroid
hormone [161].

Human TE85 osteosarcoma cells originally obtained from

J. Fogh (of Sloan-Kettering Institute, NY, NY) were also used for
these studies.
Frozen vials of cells were removed from liquid nitrogen tanks,
thawed quickly in a water bath at 37°C and aliquoted into two 10 cm
dishes containing 10 mis of DMEM + 10% bovine calf serum (the
antibiotic/antimycotic preparation from Gibco was added to the primary
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cultures with a final concentration of 1%).

All cells were grown in

humidified incubators containing 5% C02 and 95% air and the cells were
allowed to grow to a density of approximately 100 cells/mm2, which
was qualitatively assessed to be approximately 75% of confluence.
TE85 osteosarcoma cells required 2-3 days to reach this density while
the normal human bone cells required 2-3 weeks.

1)

Passing Cells:
Once cells reached the desired level of density they were

subpassaged by the following procedure.

Culture dishes would be

rinsed once with serum free DMEM to remove bovine calf serum.

This

was done because components in the serum inactivate trypsin, the
enzyme which is used to separate the monolayer of cells from the
plastic dishes.

Once the trypsin in phosphate buffered saline was

added to the cells, the dishes were placed back in the incubators for
10-15 minutes.

Inadequate exposure to trypsin resulted in cells that

remain clumped together, making the subsequent plating uneven, while
too much exposure to trypsin damaged the cells.

The trypsinized cells

were placed in a sterile centrifuge tube along with equal volumes of
DMEM + 10% bovine calf serum and centrifuged in a table top centrifuge
for 5 minutes at lOOOxg.

The cell pellet was resuspended in 10ml of

DMEM + 10% bovine calf serum and the number of cells/ml was determined
with a hemocytometer.

The number of cells counted on the grid of the

hemocytometer multiplied by 10,000 equaled the number of cells/ml.
The cells would then be diluted in DMEM + 10% bovine calf serum so
that the final plating density would be 50 cells/mm2.
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2)

Cell Freezing:
Cells would be frozen from time to time for future use.

Again,

monolayers of bone cells were released from the culture wells with
trypsin as described above.

After centrifuging, the cell pellet was

resuspended in half the desired final volume in DMEM + 10% bovine calf
serum.

An equal volume of DMEM + 10% bovine calf serum + 15% DMSO was

prepared and the two were mixed together to obtain a final DMSO
concentration of 7.5%.

This cell suspension was then aliquoted into

1ml cryogenic tubes which were then placed in a freezing container
which allowed the cells to cool down approximately 1°C/minute when the
container was placed at -70°C.

After freezing the cells at least

overnight at -70°C the cells were kept in liquid nitrogen tanks for
long term storage.

3)

Treatment of Cells With Effectors:
Once the cells reached the desired density, the cell cultures were

changed to serum free conditions for 16-24 hours before being treated
with effectors.

This was accomplished by rinsing the cells once and

then feeding them with serum free DMEM.

The effectors, solubilized in

DMEM, were added the following day and the cells were treated for the
desired time before the dishes were extracted for the cellular
proteins.

The exceptions to this procedure were the experiments which

involved growth factor treatment.

In these experiments the cells were

treated as described above except that DMEM + 0.1% bovine serum
albumin was used instead of serum free DMEM.

The bovine serum albumin

was included to prevent the growth factors from binding
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nonspecifically to the plastic walls of the test tubes and culture
dishes.

III.

Cell Proliferation Assays:
In most cases the effect on cell proliferation was assessed by a

[3H]thymidine incorporation assay.

A cell count proliferation assay

was also performed to confirm the fact that fluoride treatment can be
mitogenic for human osteoblasts.

Both assays are described as

follows.

1)

[3H]Thymidine Incorporation
The following protocol was used to assess [3H]thymidine

incorporation [162].

Cells were plated either in 24 or 48 well plates

and treated with effectors as described above.

The cells were treated

for 16-18 hours with growth factors and 20-22 hours with fluoride
before 1.5|iCi/ml of [3H]thymidine was added to each well.

The cells

were then incubated for an additional 2-5 hours before being rinsed
once with phosphate buffered saline and either frozen at -20°C or
immediately swabbed.

Frozen plates were swabbed within 2 days.

Swabbing was the process of dipping cotton swabs into 15%
trichloroacetic acid and rubbing, or swabbing, the entire surface of
each well to trap the cellular macromolecules (i.e. proteins and
nucleic acids).

The cotton swabs were then rinsed in 15%

trichloroacetic acid followed by 95% ethanol for 5-10 minutes each.
The swabs were completely dried with a blow dryer and placed in
scintillation vials along with 1ml of scintillation fluid.

The
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precipitated [3H]thymidine in the cotton swabs was counted in a
Beckman liquid scintillation counter.

At least four replicates were

used in each treatment group.

2)

Cell Counting
The cell count proliferation assay was performed by plating and

treating the cells as described above and counting the number of cells
after 48 hours.

The relative number of cells in each well was

determined by counting the cells in 5 representative areas of the
culture wells and the average was reported.

The same representative

areas were used for each well to minimize error introduced by cell
density variations on the surface of the plates.

Replicates of six

for each treatment group were used for this assay.

IV.

Phosphotyrosyl Protein Assay

1) Gel Electrophoresis
Following treatment with the various effectors, samples were
prepared for electrophoresis by extracting the cells with SDS
treatment buffer at 30°C (0.125 M Tris-Cl, 4% SDS, 20% glycerol, 10%
2-mercaptoethanol, 1 mM sodium orthovanadate, 0.01% bromophenol blue,
pH 6.8).

The dishes were rinsed once with phosphate buffered saline

and the cell monolayer was solubilized by scraping with 300-500nL of
SDS treatment buffer.

The cell extracts were immediately placed in a

boiling water bath for 2 minutes and then frozen at -20°C until they
were electrophoresed.

No extract was stored for more than 1 week

before being electrophoresed.
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SDS polyacrylamide 3-27% gradient gels with 4cm of space left at
the top were prepared for electrophoresis by pouring a stacking gel
with 10-19 lanes.

The stacking gel was made up according the

guidelines suggested by Hoefer Scientific Instruments (San Francisco,
CA).

Stock solutions of monomer (30%T 2.7%Cbis), stacking gel buffer

(0.5M Tris-Cl, pH 6.8), and 10% SDS were made up and combined with
water to form the stacking gel (2.66ml monomer solution, 5.0ml
stacking gel buffer, 0.2ml 10% SDS and 12.2ml deionized water).

This

solution was degassed under vacuum and polymerization was initiated by
the addition of 0.03g of ammonium persulfate and 20pL of TEMED.

The

solution was gently swirled and then transferred on top of the gels
with a transfer pipet.
minutes.

Complete polymerization required 30-45

After the comb was removed, the wells were rinsed with tank

buffer (0.025 M Tris-Cl, 0.192 M glycine, 0.1% SDS, pH 8.3) and the
gel was ready for sample loading.
The samples were removed from -20°C and boiled for 3 minutes
before loading 75pL for each sample.

It should be stressed that the

outside two lanes on each side of the gel should not be used for
sample loading when quantitation is needed, because the protein bands
in the outside lanes tend to spread out and run at angles making laser
densitometric quantitation extremely difficult.

Furthermore, no lanes

in the gel should be left empty because the proteins bands in the
adjacent lanes will tend to spread out, again, making quantitation
difficult.

The samples were pipeted directly at the base of the wells

prefilled with tank buffer using long tipped pipets.

Immediately

after loading the samples the gel was attached to the upper tank of a
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Hoefer Scientific SE 600 electrophoresis unit and the seal between the
gel and the tank was checked for leaks.

Any leaks were corrected and

the upper tank and gel were placed into the lower tank and the gel was
run at 4°C using 100 volts (constant voltage).

Prestained molecular

weight standards were included in each gel, and the gels were
electrophoresed until the 205kD prestained standard was at least 15mm
from the top of the gel.

2)

Transblotting
Western blotting was done in a Bio-Rad transblot cell with plate

electrodes.

The nitrocellulose membranes were wetted with transfer

buffer (0.025 M Tris-Cl, 0.192 M glycine, 20% methanol, pH 6.8) for 15
minutes prior to use.

After electrophoresis the gel was immediately

removed from the glass plates and allowed to soak in the transfer
buffer for 5 minutes before placing in the transfer sandwich.

The

transfer sandwich was made up by layering in succession, cathode side
of sandwich holder, sponge, Whatman paper, gel, nitrocellulose,
Whatman paper, sponge, anode side of sandwich holder.

The transfer

sandwich was assembled while submerged in transfer buffer being
careful to exclude air bubbles.

Once assembled, the sandwich was

placed in the transblot cell containing cold transfer buffer.

For

some experiments transfer was accomplished at 4°C using 40 V for 30
hours.

However, staining the gel following transfer indicated that a

significant amount of protein was left behind in the gel.
course led to a dilemma:

[This of

mild transfer conditions resulted in

proteins remaining in the gel, however, it is known that too
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aggressive of transfer conditions result in proteins not binding to
the nitrocellulose membranes.]

To improve the transfer of the

proteins into the nitrocellulose membrane, SDS was added to a final
concentration of 0.075% into the transfer tank after the first 30
minutes of transfer.

The addition of SDS to the transfer tank was

delayed until 30 minutes after initiating the transfer for the
following reasons;

SDS inhibits binding of proteins to nitrocellulose

membranes [163], and the proteins which transfer fastest from gels
generally bind more poorly than do slow moving proteins [164].
Therefore, SDS was added to the transfer tank after the fast moving
proteins had a chance to bind to the nitrocellulose membranes most
efficiently (without interference from SDS).

However, the SDS must be

added to the transfer tank within 4-6 hours of transfer initiation to
be effective, and so I typically added the SDS between 30-45 minutes
after beginning Western transfers.
The addition of SDS to the transfer buffer significantly enhanced
the transfer of proteins from the polyacrylamide gels.

Furthermore,

the time required to expose film was decreased with blots transferred
with SDS as compared to blots transferred without SDS, suggesting that
more protein was bound to the nitrocellulose membranes when the
transfer protocol included the addition of 0.075% SDS.

[However, it

should be noted that some proteins do not bind to the nitrocellulose
membranes even under mild transfer conditions.]
The efficiency of transfer was assessed by staining the gels with
Coomassie blue G225 following transfer.

The stain contained 0.025%

Coomassie blue G225, 7% acetic acid, and 40% methanol in water.

The
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gels were stained for 30 minutes and then rinsed once with degassed
deionized water.

The gels were then destained with 50% methanol in

water for 2-3 days.

The protein content remaining in the gels was

then quantitated by laser densitometry as described below (pg. 57).
The efficiency of protein binding to the nitrocellulose membranes
under the various conditions used was qualitatively assessed by
comparing the number of bands and their relative densities in the
autoradiograms.

While SDS is known to inhibit binding of proteins to

nitrocellulose membranes, its effect on increasing transfer of protein
from the polyacrylamide gels appeared to overcompensate for this
drawback in these studies.

3)

Immunodetection
Following transfer, the blotted nitrocellulose membrane was

briefly rinsed with running deionized water using a glass plate for
support.

The rinsing was done to remove particles of gel which stuck

to the membrane, and which if not removed created spots on the
autoradiogram.

Based on the autoradiogram, this brief rinsing

procedure did not appear to remove proteins from the nitrocellulose
membrane.

Following this rinse, the blot was air dried for at least

one hour.

The membrane was re-wetted in TNT (10mM Tris-Cl, 150mM

sodium chloride, 0.1% sodium azide, 0.075% TWEEN 20, pH 7.2) by gently
shaking for 30 minutes at room temperature.

Non-specific binding

sites on the membrane were then blocked by incubating the membrane for
30 minutes in 200mls of blocking buffer (TNT + .5% bovine serum
albumin).

It is important to note that longer blocking times tended
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to increase the background of the autoradiogram and result in the loss
of antigens from the membrane [165].

Following the blocking step, the

blot was placed in a heat sealable bag containing 15ml of monoclonal
antiphosphotyrosine antibody solution (PY69 or PY20 diluted to 1 |ig/ml
in blocking buffer) for 2-3 hours at room temperature.

One corner of

the bag was cut and the antibody solution was removed by rinsing once
with TNT.

Protein A, radio-iodinated by the chloramine T method

[166], was diluted in blocking buffer (1 million counts per minute/ml)
and then placed with the blot for 1 hour.

The blot was rinsed 5 times

with blocking buffer and once with TNT before being drip dried and
placed in a new heat sealable bag.

One edge of the bag was not

completely sealed to prevent air pockets forming between the blot and
the film during film exposure.

4)

Densitometry
Phosphotyrosine on the blot was visualized by autoradiography.

The treated blot was placed in a Kodak X-Omatic cassette with Dupont
Cronex Lightning Plus intensifier screens and film.

The cassette was

loaded by layering, in succession, intensifier screen, blot, film and
second intensifier screen.

The film was exposed for 2 hours to 7 days

at -70°C depending on the amount of radioactivity bound to the blot
before being developed in a Kodak x-ray film developer.
Densitometric analysis of the autoradiograms was accomplished with
a 1D/2D Soft Laser Scanning Densitometer and ERIS Reporting
Integrating System from BIOMED Instruments, Inc. (Fullerton, CA).
Operation of the densitometer consisted of; a) selecting an
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appropriate laser width, b) aligning the autoradiogram so that the
laser completely contacted each band, c) adjusting the gain and zero
settings so that the darkest band to be scanned absorbed approximately
75% of the emitted laser, while the lightest region to be scanned
absorbed none, and d) storing the results of each scan on a computer
disk for detailed processing.

The data processing was performed with

the ERIS Reporting Integrating System, which is capable of extensive
band analysis and artifact handling.

The densitometric values from

this system were given as areas, with larger integrated areas being
considered more dense.

In this dissertation, these data were

expressed as % relative density, or, stated differently, the area of
each band was expressed as a percentage of the area of the control
bands (i.e. the area of the treatment bands was divided by the area of
the control bands and the resulting number was multiplied by 100).

5)

Intra-Assay Variation
To determine the magnitude of change in % relative density which

would be required for the change to be statistically significant, the
intra-assay variation of the immunodetection method used for these
experiments was assessed.

Nine replicate plates of TE85 cells were

grown as described above and the cellular proteins were run on gels
and immunoblotted.

The resulting autoradiogram was quantitated by

laser densitometry and the average densitometric value and %
coefficient of variance was determined for several molecular weight
protein bands (see results pg. 61).

55

V.

Protein Assays
Protein content of samples was assessed by three different

methods, the Folin-Lowry protein assay, for samples specifically
prepared for protein analysis, a modified Folin-Lowry protein assay,
for samples which had been extracted with SDS-PAGE treatment buffer,
and densitometric analysis of gels stained with Coomassie blue
following Western transfer.

1)

Folin-Lowry Protein Assay
Samples were prepared for the Folin-Lowry protein assay by

extracting cell culture monolayers with 1.0 M sodium hydroxide.

The

cells were grown in 6 well culture plates and were rinsed three times
with PBS before 500pL of 1.0 M sodium hydroxide was added to each
wel 1.

The plates were shaken for 15 minutes at room temperature and

then the contents of each well were homogenized by passing them
through a 26 gauge needle four times.

Sample extract (200|iL) was

combined with lOOpL of water followed by lOOpL of a reaction mixture
(the reaction mixture was made by combining 8ml of 25% Na2C03

1ml 1%

CuS04 and 1ml 2% Na-K-tartrate, and this mixture was made fresh from
the indicated stock solutions for each assay) and allowed to stand at
room temperature for 10 minutes.

At this point 1.0 ml of dilute Folin

reagent (i.e. 17.5ml of water to 1.0ml of concentrated reagent) was
mixed in with each sample and then placed at 37°C for 20 minutes.

The

samples were then cooled to room temperature for 5 minutes and 200pL
was pipeted in duplicate for each sample into a 96 well plate.

The

absorbance of the samples was determined at 660nm in an EAR 400 AT
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microplate reader from SLT Labinstruments (Austria).

A standard curve

was used for each assay, and was prepared by dissolving 100 pg of
bovine serum albumin in 200pL of 1.0 M sodium hydroxide and serially
diluting the standard with more sodium hydroxide.

The standard was

then run in parallel with the experimental samples.

2)

Modified Folin-Lowry Protein Assay
The modified Folin-Lowry protein assay was necessary to determine

the protein content of samples which had been prepared for SDS-PAGE by
extracting with treatment buffer (see above).

The stock solutions

required for this assay included copper-tartrate-carbonate (CTC)
solution (0.1% copper sulfate-5H20, 0.2% potassium tartrate, 10%
sodium carbonate), 10% SDS, 1.0 M sodium hydroxide and concentrated
Folin-Ciocalteu phenol reagent.

Working solutions of 0.15% sodium

deoxycholate, 72% trichloroacetic acid, Img/ml bovine serum albumin,
reagent A (equal parts of stock CTC, SDS and water), reagent B (one
volume of concentrated Folin-Ciocalteu phenol reagent mixed with five
volumes of distilled water), and absolute ethanol chilled with dry ice
were used for the assay.

The first step was to precipitate the

proteins from the treatment buffer.

This was accomplished by bringing

the sample to a total volume of 1.0ml with distilled water and adding
0.1ml of 0.15% sodium deoxycholate.

The solution was mixed and

incubated at room temperature for 10 minutes before adding 0.1ml of
72% trichloroacetic acid.

After mixing, the samples were placed on

ice for 10 minutes and then centrifuged at SOOOxg for 15 minutes.

The

supernatant was discarded from the tubes and the pellets were washed
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twice with the absolute ethanol chilled with dry ice.
placed upside down on absorbent paper until dry.

The tubes were

The pellets were

dissolved in 0.25ml of 1.0M NaOH and then 0.75ml of reagent A was
added and mixed.

0.5ml of reagent B was then added and the solution

was immediately mixed.

After 30 minutes at room temperature the

absorbance was recorded at 660nm using an EAR 400 AT microplate reader
from SLT Labinstruments (Austria).

To create a standard curve, 5, 10,

20 and 40pg of bovine serum albumin were dissolved in SDS treatment
buffer and were run in parallel with the experimental samples
beginning with the precipitation step.

3)

Densitometric Analysis of Stained Gels
Electrophoresed gels were stained with Coomassie blue (as

described above, pg. 50) following Western blotting, and the amount of
protein in the gels was quantitated by laser densitometry.

The

densitometric analysis of the stained gels was essentially the same
method used for the autoradiograms (described above, pg. 52), except
that the total amount of protein in each lane was estimated in
addition to scanning individual protein bands across all lanes.

The

total amount of protein in each lane was determined by setting the
laser width to match the width of the lanes in the gels, and scanning
the bands in each lane together (rather than scanning individual bands
across the gel), generating one area which represented the sum of all
the areas of the individual protein bands in each lane.

This total

area was then used to compare the relative amount of protein loaded in
each lane.
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VI.

Electromagnetic Field Exposure:
The electromagnetic field exposure system was comprised an FG2

function generator and UC-10 wave counter obtained from Circuitmate, a
division of Beckman Co (Palo Alto, CA), a DM 2220 magnetometer from
Schonstedt Instrument Co (Reston, VA), a T921 oscilloscope from
Tektronix (Beaverton, OR) and a custom designed Helmholtz coil
apparatus built by Dr. Robert Fitzsimmons.

The custom apparatus

consisted of a 30 cm diameter Helmholtz coil pair made from 400 turns
of #28 AWG magnet wire supported by a nonconducting, nonmagnetic
polymeric frame.

The coils were oriented horizontally and produced a

vertically oriented magnetic field.

The static and dynamic magnetic

fields were created by the same pair of Helmholtz coils (i.e. the
static and dynamic magnetic fields were parallel to each other).

The

amplitude and DC offset controls of the function generator were used
to control the amplitudes of the magnetic fields.

The amplitude of

the AC magnetic field was 0.400 Gauss peak-to-peak with 5.3 mA rms
through the Helmholtz coils and the amplitude of the DC magnetic field
was 0.200 Gauss with 7.5 mA through the Helmholtz coils.

The

magnitude and directions of the ambient horizontal and vertical
geomagnetic fields were measured and recorded during each experiment.
The average values for the vertical DC component was 400+/-20
milligauss and the horizontal component was 150+/-16 milligauss.
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VII.

Statistical Analysis
Statistical analysis of the experiments performed in these studies

was accomplished as follows.

When there was a control group

associated with each treatment group

the two-tailed Student-t test

was used to determine if the respective treatment caused any
statistically significant change in the measured parameter (a p value
of <0.05 was set as the level which would be considered statistically
significant for most of these studies).

However, when one control

group was used for multiple treatment groups, ANOVA was used to
determine if significant differences existed.

If ANOVA indicated that

there were significant differences between the groups, then the twotailed Student-t test was used to determine which treatment groups
differed significantly from controls.

The p values obtained from each

type analysis were compared and only the more conservative p value was
reported in these studies (for example, if the Student-t test gave a p
value of <0.001 while ANOVA gave a p value of <0.01, p<0.01 would be
reported).
While the level of significance was set at p<0.05 for many of the
experiments performed during these studies, the level used to
determine significant changes for the densitometric analysis was
actually set at p<0.02.

This value was chosen because it incorporated

the largest % coefficient of variation observed when the intra-assay
variation was determined for the immunoblot assay.

CHAPTER THREE

RESULTS
I. Assay for Steady State Cellular Levels of Tyrosyl
Phosphorylation
The immunoblot assay used for these studies contains several
important variables that must be controlled: a) protein loading in the
polyacrylamide gels, b) the specificity of the monoclonal
antiphosphotyrosine antibody, and c) the reproducibility of the
immunoblot assay.

The following sections will deal with each of these

issues.

1)

Protein Loading of Samples
The amount of protein in samples loaded into polyacrylamide gels

can affect the amount of tyrosyl phosphorylation detected.

Several

factors are capable of influencing the final amount of protein in each
sample, including cell plating, cell extraction and protein synthesis
stimulated by effector treatment (effector stimulated protein
synthesis would systematically increase the amount of protein in the
treated samples relative to the controls, resulting in "reproducible"
increases in factor-dependent tyrosyl phosphorylation).
To determine whether protein loading was a significant variable in
this immunoblot assay, two studies were performed.

First, to

determine whether the cell culture procedures and prolonged treatments
with fluoride affected total cellular protein content, the protein
level was measured in cells cultured for 4 and 22 hours in the absence
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and presence of mitogenic concentrations of fluoride (100-200pM).

No

significant differences in protein levels were observed (data not
shown).

In the second study, cellular proteins were separated by SDS-

PAGE and the protein bands were stained with Coomassie blue.

The

relative amount of protein in each lane was quantitated by laser
densitometry of the stained gels.

This study showed that variation in

the amount of protein loaded in the gels was less than 10% (data not
shown).

Based on these findings, it was concluded that the variable

of protein loading in the polyacrylamide gels did not appear to be a
significant problem for these studies.

2)

Antibody Specificity
While the commercial supplier claimed that the antibody was

specific for phosphotyrosine, it was essential to demonstrate that the
antibody was specific for phosphotyrosine under the conditions used
for these studies.

In this regard, I have tested the specificity of

the monoclonal antiphosphotyrosine antibody by using human epidermoid
carcinoma A431 cell membranes, which contain 10-100 times more EGF
receptors than other cell types.

The EGF receptor is a 170kD protein

which contains intrinsic tyrosyl kinase activity capable of
autophosphorylation when cells are treated with EGF [71].

Therefore,

A431 cell membranes separated by polyacrylamide gel electrophoresis
exhibit a high level of tyrosyl phosphorylation at 170kD.
In this experiment, autophosphorylated A431 cell membrane proteins
were separated on a 10-20% gradient gel and transferred to a
nitrocellulose membrane.

The blot was cut into 4 strips, each
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containing a lane with equivalent amounts of A431 cell membrane
proteins.

The strips were incubated with either Ipg/ml

antiphosphotyrosine antibody alone or Ipg/ml anti-phosphotyrosine
antibody plus 5mM phosphotyrosine, phosphothreonine or phosphoserine,
respectively.

Figure 6 shows that the inclusion of phosphotyrosine

completely abolished the 170kD protein band (presumably the tyrosyl
phosphorylated EGF receptor), whereas inclusion of either
phosphoserine or phosphothreonine had non-significant effects on the
relative density of the 170kD EGF receptor band.

These results

indicate that the commercial antiphosphotyrosine antibody is specific
for phosphotyrosine under the conditions used for these experiments.

3)

Reproducibility of the Immunoblot Assay
One of the limitations of the immunoblot assay is the practical

limit to the number of replicates that can be performed for any given
experiment.

Most investigators have been satisfied by showing time-

dependent and dose-dependent changes in phosphorylation in response to
effector treatments.

Once the observations were repeated, the changes

in phosphorylation were accepted as significant even though the sample
size may have been as small as one.

The changes in phosphorylation by

agents that stimulate tyrosyl protein kinases have typically been
large enough so that the validity of this approach has not been
questioned.

However, I was interested in defining a level of change

in phosphorylation which could be considered statistically
significant.

Therefore, an experiment was performed to determine the

magnitude of change from control in densitometric values which would
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FIGURE 6. Specificity of Anti-Phosphotyrosine antibody.
Four identical aliquots from a sample of phosphorylated A431
cell membrane proteins were separated by SDS-PAGE and
transblotted onto a supported nitrocellulose membrane. The
membrane was cut into four strips, each containing one lane
of phosphorylated A431 cell membrane proteins. The strips
were incubated with the antibody alone (Ab) or with antibody
plus 5mM phosphotyrosine (5mM Tyr), 5mM phosphoserine
(5mM Ser) or 5mM phosphothreonine (5mM Thrl^s competing
agents. The blots were then incubated with P25!] Protein A
and the bands were visualized and the relative density of
the 170kD protein band on the autoradiogram was quantitated
as described in the methods. The 170kD protein band is
shown in the photograph. The shaded area on the graph
represents the region of insignificant change (i.e. the %
relative densities which fall outside the shaded region may
be considered significant, please see Table 2).
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be needed in order for the change to be considered statistically
significant (p<0.05).

To my knowledge, this type of quantitative

analysis of the immunoblot assay has not been previously reported.
To determine the intra-assay variation for the immunodetection of
phosphotyrosyl proteins, 9 replicate dishes of TE85 cells were
prepared and electrophoresed.
shown in Table 2.

The resulting densitometric analysis is

The autoradiographic densities of the bands with

the indicated apparent molecular weights were quantitated and the
standard deviations were calculated.

The average % coefficient of

variance was shown to be 25%, indicating that for 95% confidence
limits, any change greater than 2 standard deviations (i.e. 50% above
control values) may be considered significant.

However,

to be

conservative, this dissertation considered a change significant only
if the change was greater than 70% above controls (since the largest %
coefficient of variation was 35%).

In other words, 98% confidence

limits were used for these experiments.

II. Fluoride
1)

Fluoride Induced Mitogenesis
One of the primary goals of this work was to investigate the

effects of mitogenic doses of fluoride on steady state levels of
tyrosyl phosphorylation in human bone cells.

Before that could be

accomplished, however, it was necessary to demonstrate that fluoride
was indeed mitogenic for human bone cells under my experimental
conditions.

Accordingly, initial work was performed to demonstrate

that human osteoblasts responded to fluoride mitogenically.
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TABLE 2.
Intra-Assay Variation.
Nine replicates of TE85 cells were prepared and
electrophoresed. The average densitometric values and
standard deviations were determined for the indicated
molecular weight bands from the autoradiogram. % coefficient
of variation was defined as the average densitometric value
divided by its respective standard deviation. The %
coefficient of variation did not exceed 35%.

Number of
Replicates

Apparent
M.W. (kD)

Confidence
Limits (95%)

% Coefficient
of Variation

220

9

25

50

154

9

34

68

114

9

16

32

90

9

20

40

61

9

21

42

48

9

29

58

36

9

21

42

30

9

25

50

22

9

35

70
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Osteoblasts from several bone sites were tested for their ability
to proliferate in response to fluoride treatment.

There were three

basic reasons for screening osteoblasts from multiple bone sites:
First, since fluoride’s ability to stimulate osteoblast proliferation
is questioned by some investigators, a demonstration that fluoride can
be mitogenic for osteoblasts from multiple skeletal sites would
further support the view that fluoride is a potential osteoblast
mitogen.

Second, since fluoride induced cell proliferation appears to

be tissue specific, a comparison of the changes in tyrosyl
phosphorylation from the different osteoblasts could aid in
understanding the mechanism by which fluoride stimulates osteoblast
mitogenesis.

Finally, at the onset of these studies it was not yet

determined which osteoblast-like cell line would be easiest to work
with, and so it was of interest to have several cell lines available
which responded mitogenically to fluoride to ensure that progress on
this project would not be impeded for technical reasons.
Figure 7 (panels a, b and c) demonstrates that fluoride was
mitogenic for human osteoblast-like cells of mandibular, rib and bone
marrow origins.

Fluoride treatment of these cells resulted in

q

increased [0H]thymidine incorporation as compared to untreated
controls.

To rule out the possibility that increased thymidine

incorporation was artifactually caused by an increase in [3H]thymidine
uptake, the mitogenic effects of fluoride were confirmed in TE85
osteosarcoma cells by a cell count proliferation assay (Figure 7,
panel d).

00

FIGURE 7. Fluoride induced osteoblast mitogenesis.
Panel a shows the effect of the indicated concentrations of
fluoride on normal human mandibular osteoblast-like cell
proliferation as determined by [3H]thymidine incorporation.
Statistical analysis of the results showed that both 50pM
fluoride and 100pM fluoride significantly increased
[3H]thymidine uptake by 25%. 200pM fluoride showed no
significant effect. The error bars represent SEM with a
sample size of 12.
Panel b shows the effect of fluoride on normal human rib
osteoblast-like cells. 50pM fluoride increased [3H]thymidine
incorporation in a statistically significant manner. The other
indicated concentrations of fluoride had no statistically
significant effect. The error bars represent SEM with a
sample size of 4.
Panel c shows fluoride’s effect on normal humam bone
marrow osteoblast-like cells as determined by [3H]thymidine
incor poratian. 50pM and 100pM fluoride significantly
increased [3H]thymidine incorporation. The error bars
represent SEM with a sample size of 12.
Panel d shows the effects of fluoride on TE85 osteosarcoma
cell proliferation. TE85 cells were treated with the indicated
concentrations of fluoride for 48 hours and the cells were
counted as described in the methods section. SOpM, KDOpM
and 200pM fluoride significantly increased the cell number.
Error bars represent SEM with a sample size of 6.
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Based on these findings, it was concluded that fluoride was
mitogenic for human osteoblast-like cells under the conditions used in
these studies.

2)

Fluoride Induced Tyrosyl Phosphorylation
To determine if mitogenic concentrations of fluoride could alter

cellular levels of tyrosyl phosphorylation, time-course experiments
were performed.

The time courses should also reveal relevant

information regarding the question as to whether fluoride affects the
steady state level of tyrosyl phosphorylation by altering the
activities of tyrosyl protein kinases or PTPPs.

It is reasoned that

if fluoride acts to increase tyrosyl phosphorylation by activation of
a tyrosyl kinase activity, the effects should be immediate.

On the

other hand, if fluoride induced tyrosyl phosphorylation is mediated by
an inhibition of a PTPP activity, the effects should be accumulative
and require hours instead of minutes to be observed.

Figure 8 shows

that fluoride treatment of TE85 osteoblast-like cells for times
shorter than 8 hours did not appear to have a statistically
significant effect on steady state levels of tyrosyl phosphorylation.
However, there may have been some acute effects on tyrosyl
phosphorylation induced by fluoride which were not detected due to
limitations in the immunoblot assay.

On the other hand, when these

cells were exposed to mitogenic concentrations of fluoride for time
periods longer than 8 hours, steady state levels of tyrosyl
phosphorylation of cellular proteins with apparent molecular weights
Of 244kD, 220kD, 170kD, 96kD, 62kD, 48kD, 34kD and 32kD were

(-*

FIGURE 8. Fluoride induced time-dependent changes in
tyrosyl phosphorylation. Fluoride’s effect on the steady
state levels of tyrosyl phosphorylation in TE85 osteoblast-like
cells treated with either 50pM or 100pM fluoride for various
times (1 minute to 24 hours) was determined. Significant
changes in tyrosyl phosphorylation were observed in bands
with the indicated apparent molecular weights. The shaded
area indicates the region in which changes in relative
density do not differ significantly from controls. The
protein bands were arbitrarily divided into two panels to
facilitate reader viewing.
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significantly increased as compared to controls (i.e. > 170% of
controls).
The dose-dependence of fluoride mediated tyrosyl phosphorylation
was investigated in both human TE85 osteosarcoma and normal human rib
osteoblast-like cells.

Human TE85 cells were treated with 50pM, lOOpM

and SOOpM concentrations of fluoride for 24 hours.

Figure 9 indicates

that there were dose-dependent changes in the steady state level of
tyrosyl phosphorylation of several protein bands (apparent molecular
weights of 62kD, 48kD, 34kD and 32kD).

The steady state levels of

tyrosyl phosphorylation of the 62kD and 48kD protein bands increased
steadily as the concentration of fluoride approached 500pM.

However,

the changes in the steady state levels of tyrosyl phosphorylation of
the 34kD and 32kD bands were biphasic in nature, with the maximal
stimulation of tyrosyl phosphorylation occurring at approximately
lOOpM fluoride.

The normal human rib osteoblast-like cells were

treated with lOpM, 25|iM, 50pM, 100|iM and 200|iM concentrations of

fluoride for 19.5 hours.

The steady state levels of tyrosyl

phosphorylation of protein bands with apparent molecular weights of
220kD, 170kD, 48kD, 34kD and 32kD were increased by fluoride treatment
in dose-dependent manners (Figure 10).

The increase in tyrosyl

phosphorylation of the 170kD band increases steadily as the
concentration of fluoride approached 200pM, while the increases in
tyrosyl phosphorylation of the 220kD, 48kD, 34kD and 32kD bands were,
again, biphasic in nature and maximal at a fluoride concentration of
100|iM.
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FIGURE 9a. Photograph of autoradiogram showing fluoride
induced dose-dependent changes in tyrosyl phosphorylation
as determined in TE85 cells. The effects of 50pM, lOOpM and
500pM concentrations of fluoride on steady state levels of
tyrosyl phosphorylation were determined in TE85 cells at 24
hours. Significant changes in tyrosyl phosphorylation were
observed in bands with the indicated apparent molecular
weights (right side of photo).

75

76

FIGURE 9b. Densitometric analysis of autoradiogram showing
fluoride induced dose-dependent changes in tyrosyl
phosphorylation as determined in TE85 cells. Significant
changes in tyrosyl phosphorylation were observed in bands
with the indicated apparent molecular weights. The shaded
area indicates the region in which changes in relative
density do not differ significantly from controls.
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FIGURE 10. Fluoride induced dose-dependent changes in
tyrosyl phosphorylation as determined in normal human rib
osteoblast-like cells. The effects of lOpM, 25pM, 50pM, IOOjjM
and 200pM concentrations of fluoride on the steady state
level of tyrosyl phosphorylation in normal human rib
osteoblast-like cells was determined at 19.5 hours.
Significant changes in tyrosyl phosphorylation were observed
in bands with the indicated apparent molecular weights. The
shaded area indicates the region in which changes in relative
density do not differ significantly from controls.
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An important observation is that the dose-dependency of some of
the changes in tyrosyl phosphorylation induced by fluoride appeared to
correlate with fluoride induced osteoblast proliferation.

For the

TE85 cells, the dose-dependent changes in tyrosyl phosphorylation of
the 34kD and 32kD protein bands appeared to correlate with the doseresponse curve of fluoride to stimulate bone cell proliferation.

Both

sets of curves showed similar biphasic responses, with maximal changes
near 100|iM fluoride.

For the normal human rib osteoblast-like cells,

the 220kD, 48kD, 34kD and 32kD protein bands also exhibited biphasic
induction of tyrosyl phosphorylation in response to fluoride
treatment.

Again, the maximal responses in proliferation and

phosphorylation occurred near lOOpM fluoride.
To further evaluate whether or not fluoride-dependent changes in
tyrosyl phosphorylation correlate with osteoblast proliferation, the
tissue specificity of fluoride induced cell proliferation was
exploited.

Experiments were performed comparing the effects of

fluoride on steady state levels of tyrosyl phosphorylation in cells
which responded mitogenical1y to fluoride (human osteoblast-like
cells) versus cells which did not (human foreskin fibroblasts [167]).
Figure 11 shows the comparison of tyrosyl phosphorylation patterns
between normal human mandibular osteoblast-like cells and human skin
fibroblasts treated with 50|iM fluoride.

This concentration of

fluoride increased the steady state levels of tyrosyl phosphorylation
in the osteoblast-line cells (protein bands with apparent molecular
weights of 148kD, 72kD, 62kD, 50kD and 48kD).

In contrast, the human
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FIGURE 11a. Photograph of autoradiogram showing fluoride
induced tyrosyl phosphorylation compared in cell types which
differ in their ability to respond mitogenically to fluoride.
The effect of SOpM fluoride on tyrosyl phosphorylation was
compared between normal human mandibular osteoblast-like
cells and human skin fibroblasts. The cells were treated for
22 hours. The osteoblast-like cells showed significant
changes in tyrosyl phosphorylation at 148kD, 72kD, 62kD,
50kD and 48kD, while the human skin fibroblasts exhibited no
fluoride dependent changes in their level of tyrosyl
phosphorylation.
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FIGURE 11b. Densitometric analysis of autoradiogram showing
fluoride induced tyrosyl phosphorylation compared in cell
types which differ in their ability to respond mitogenically to
fluoride. The osteoblast-like cells showed significant changes
in tyrosyl phosphorylation at 148kD, 72kD, 62kD, 50kD and
48kD, while the human skin fibroblasts exhibited no fluoride
dependent changes in their level of tyrosyl phosphorylation.
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foreskin fibroblasts showed no significant increases in steady state
levels of tyrosyl phosphorylation.
To determine if fluoride-dependent changes in tyrosyl
phosphorylation were reversible, TE85 cells were treated with fluoride
for 23 hours, at which time half of the treatment groups had the
fluoride removed by rinsing the culture dishes twice with fresh DMEM.
At 24 hours the incubations were terminated, and the cellular proteins
were processed (Figure 12).

A protein with an apparent molecular

weight of 244kD had its level of tyrosyl phosphorylation increased by
the continued presence of fluoride.

When fluoride was removed, the

level of tyrosyl phosphorylation of the 244kD protein band returned to
basal levels, suggesting that the effect of fluoride was rapidly
reversible.

III. Effects of Other Bone Cell Mitogens on Steady
State Tyrosyl Phosphorylation Levels of Cellular
Proteins in Human Bone Cells
1)

Sodium Orthovanadate
To demonstrate that vanadate was indeed mitogenic for human

osteoblast-line cells, the dose-dependent effects of vanadate on
thymidine incorporation was evaluated (Figure 13).

The upper panel in

Figure 13 shows that 2.5|iM, 5pM and lOpM concentrations of vanadate
significantly increased DNA synthesis in normal human mandibular
osteoblast-like cells, whereas a concentration of vanadate of 15pM
significantly inhibited DNA synthesis in normal human mandibular
osteoblast-like cells.

The lower panel in Figure 13 shows that 2|iM,
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FIGURE 12. Reversibility of fluoride induced tyrosyl
phosphorylation. To determine if the fluoride induced
tyrosyl phosphorylation was reversible, TE85 cells were
treated with 100pM fluoride for 23 hours at which time, half
of the treated plates were rinsed twice with DMEM to remove
fluoride. All of the plates were then extracted at 24 hours.
Laser densitometric analysis of the autoradiogram indicated
that a protein with an apparent molecular weight of 244kD
had an elevated level of tyrosyl phosphorylation in the
presence of fluoride. With fluoride removal, the level of
tyrosyl phosphorylation of the same band returned to basal
levels. The 244kD band from two representative lanes from
each group is shown in the photograph, and the error bars
represent SEM with a sample size of four.
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FIGURE 13. Vanadate induced human bone cell proliferation.
The effect of the indicated concentrations of vanadate on
normal human mandibular osteoblast-like cell proliferation and
bijman TE85 osteosarcoma cell proliferation was assessed by
[3H]thymidine incorporation. All indicated concentrations of
vanadate had statistically significant effects. The error bars
represent SEM with sample sizes of 6.
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5(iM and IOjiM concentrations of vanadate significantly increased DNA
synthesis in human TE85 osteosarcoma cells.

These findings indicate

that the human bone cells used for these studies responded
mitogenical1y to vanadate.
Figure 14 indicates the dose-dependent effects of vanadate
treatment on steady state levels of tyrosyl phosphorylation.

TE85

cells were treated with varying doses of vanadate (i.e. 2-13pM) for 24
hours, and bands with apparent molecular weights of 96kD, 68kD and
38kD exhibited dose-dependent changes in their steady state level of
tyrosyl phosphorylation in response to vanadate treatment.
To determine time-dependent changes in tyrosyl phosphorylation in
response to vanadate treatment, TE85 cells were treated with 5pM
vanadate for times ranging from 10 minutes to 9 hours (Figure 15).
Vanadate treatment induced time-dependent increases in the steady
state levels of tyrosyl phosphorylation of protein bands with apparent
molecular weights of 244kD, 220kD, 148kD, 73kD, 68kD, 62kD, 48kD,
44kD, 41kD, 38kD, 34kD and 32kD, some of which (e.g. 244kD, 220kD,
62kD, 48kD, 34kD and 32kD bands) had their level of tyrosyl
phosphorylation increased by fluoride treatment.
While some of the protein bands exhibited increases in tyrosyl
phosphorylation in response to both vanadate and fluoride, the timedependence of the changes induced by each factor was dramatically
different; vanadate induced increases in steady state levels of
tyrosyl phosphorylation within minutes, while fluoride treatment
required hours before significant changes were observed.
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FIGURE 14a. Photograph of autoradiogram showing dose
dependent effects of vanadate on steady state levels of
tyrosyl phosphorylation. The effect of varying
concentrations of vanadate (2pM, 5pM, 7pM, 10pM and 13pM)
on the steady state level of tyrosyl phosphorylation was
determined in TE85 cells at 24 hours,
Protein bands with
apparent molecular weights of 96kD, 68kD and 38kD exhibited
significant increases in their levels of tyrosyl
phosphorylation in dose-dependent manners.
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FIGURE 14b. Densitometric analysis of autoradiogram showing
dose dependent effects of vanadate on steady state levels of
tyrosyl phosphorylation. Protein bands with apparent
molecular weights of 96kD, 68kD and 38kD exhibited
significant increases in their levels of tyrosyl
phosphorylation in dose-dependent manners. The shaded
area indicates the region in which changes in relative
density do not differ significantly from controls.
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FIGURE 15a. Photograph of autoradiogram showing timedependent changes in steady state levels of tyrosyl
phosphorylation in response to a mitogenic concentration of
vanadate. To determine if vanadate treatment of TE85 cells
would induce tyrosyl phosphorylation in a time-dependent
manner, TE85 cells were treated for various times (10 minutes
to 9 hours) with 5pM vanadate. The apparent molecular
weight for each protein band which exhibited significant
changes in tyrosyl phosphorylation is indicated.
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FIGURE 15b. Time-dependent changes in steady state levels
of tyrosyl phosphorylation in response to a mitogenic
concentration of vanadate. The apparent molecular weight
for each protein band is indicated and the shaded area
indicates the region in which the changes in relative density
were not significantly different form controls. The protein
bands were arbitrarily divided into two panels to facilitate
reader viewing.
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2)

Growth Factors Whose Receptors are Tyrosyl

Protein Kinases
Bone cells are known to produce and respond to several growth factors
including, IGF-I, PDGF and EGF.

The mitogenic activity of these

growth factors has been suggested to be mediated at least in part by
activation of their receptor tyrosyl kinase activities.
To demonstrate that these growth factors were mitogenic for
q

osteoblast-like cells, the effects of lOng/ml on [ H]thymidine
incorporation were determined for IGF-I, PDGF and EGF (Table 3).

DNA

synthesis in these cells was increased in a statistically significant
manner by each factor.
IGF-I treatment increased the level of tyrosyl phosphorylation of
proteins with apparent molecular weights of 220kD and 96kD in human
mandibular cells (Figure 16).

The mandibular cells were used to

determine the effects of IGF-I instead of TE85 cells because the
mandibular cells do not produce as much endogenous IGF-I [194].

It

should be stressed that fluoride treatment of osteoblast-like cells
also resulted in increased levels of tyrosyl phosphorylation of these
two molecular weight protein bands.

Furthermore, when cells were

pretreated with mitogenic concentrations of fluoride for 30 minutes,
IGF-I-dependent increases in the level of tyrosyl phosphorylation of a
170kD protein band occurred at 5 minutes as compared to 30 minutes
which was required with IGF-I alone in a separate experiment (data not
shown).
PDGF increased the level of tyrosyl phosphorylation of bands with
apparent molecular weights of 244kD, 220kD, 180kD, 148kD, 41kD, 36kD

1 00

TABLE 3. Growth Factor Induced Cell Proliferation. The
effects of IGF-I, PDGF and EGF on osteoblast-like cell
proliferation were determined by [3H]thymidine incorporation.
Each growth factor significantly increased DNA synthesis,
and the results are shown as mean ± SEM. Normal human
mandibular cells (Man) and TE85 cells were used.

Growth
Factor

Concentration

% Control

P Value

IGF-I

lOng/ml

206 + /-20

<0.001

6

Man

IGF-I

50ng/ml

136 + /-11

<0.05

6

TE85

PDGF

lOng/ml

317 + /-20

<0.001

6

Man

PDGF

lOng/ml

128 + /-6

<0.001

12

TE85

EGF

lOng/ml

173 +/-18

<0.001

6

Man

EGF

lOng/ml

137 +MO

<0.01

6

Te85

Cell

Sample
Size

Type
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FIGURE 16. IGF-l-dependent tyrosyl phosphorylation. The
effect of 10ng/ml of IGF-I on tyrosyl phosphorylation was
determined in normal human mandibular osteoblast-like cells
at 5 minutes. Proteins with apparent molecular weights of
220kD and 96kD had their level of tyrosyl phosphorylation
increased by IGF-I treatment.
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and 23kD in a time-dependent manner (figure 17).

Fluoride treatment

also increased the level of tyrosyl phosphorylation of two of the same
molecular weight protein bands (e.g. 244kD and 220kD protein bands).
EGF induced large increases in tyrosyl phosphorylation of bands
with apparent molecular weights of 244kD, 220kD, 170kD, 148kD, 106kD
and 96kD at 10 minutes (Figure 18).

However, by 60 minutes, only the

148kD band remained phosphorylated above control values and by 3 hours
no significant differences in tyrosyl phosphorylation could be
detected.

It should be pointed out that fluoride-dependent changes in

tyrosyl phosphorylation also occurred in protein bands with apparent
molecular weights of 244kD, 220kD, 170kD and 97kD.

3)

Growth Factor Whose Receptor has no Tyrosyl

Protein Kinase Activity
The effect of IGF-II on normal human mandibular osteoblast-like
cell proliferation was determined.

Figure 19 shows that a

concentration of lOng/ml of IGF-II significantly increased DNA
synthesis in these cells.

Similar results were obtained in TE85 cells

(data not shown).
IGF-II treatment of TE85 cells increased the steady state level of
tyrosyl phosphorylation of proteins with apparent molecular weights of
400kD, 280kD, 220kD and 96kD in a time-dependent manner (Figure 20).
The 220kD and 96kD protein bands were also phosphorylated by mitogenic
concentrations of fluoride in osteoblast-like cells.
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FIGURE 17a. Photograph of autoradiogram showing PDGF
induced tyrosyl phosphorylation. TE85 cells treated with
lOng/ml of PDGF for the indicated times showed timedependent changes in the levels of tyrosyl phosphorylation
of proteins with apparent molecular weights of 244kD, 220kD,
180kD, 148kD, 41 kD, 36kD and 23kD. The 148kD, 41 kD, 36kD
and 23kD bands were unquantifiable at 5 minutes due to
defects in the autoradiogram.
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FIGURE 17b. Densitometric analysis of autoradiogram showing
PDGF induced tyrosyl phosphorylation. The shaded area
indicates the region in which changes in relative density do
not differ significantly from controls.
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FIGURE 18a. Photograph of autoradiogram showing EGF
induced tyrosyl phosphorylation. The effect of 10ng/ml of
EGF on tyrosyl phosphorylation was determined in TE85 cells
at the indicated times. Significant changes in tyrosyl
phosphorylation were observed in bands with the indicated
apparent molecular weights.
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FIGURE 18b. Densitometric analysis of autoradiogram showing
EGF induced tyrosyl phosphorylation. The shaded area
indicates the region in which changes in relative density do
not differ significantly from controls.
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Figure 19. IGF-II induced cell proliferation. The effect of
IGF-II on normal human mandibular osteoblast-like cell
proliferation was determined. 10ng/ml of IGF-II significantly
increased DNA synthesis in these cells as assessed by
[3H]thymidine incorporation. The error bars represent SEM,
with a sample size of six. Similar results were obtained with
TE85 cells (data not shown).
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FIGURE 20. IGF-II induced tyrosyl phosphorylation. The
effect of 30ng/ml of IGF-II on tyrosyl phosphorylation was
determined in TE85 cells at the indicated times. Proteins
with apparent molecular weights of 400kD, 280kD, 220kD and
96kD had their level of tyrosyl phosphorylation significantly
increased by IGF-II treatment. The shaded area indicates
the region in which changes in relative density do not differ
significantly from controls.
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4)

Electromagnetic Fields
Prior to determining the effects of electromagnetic field exposure

on tyrosyl phosphorylation, it was demonstrated that electromagnetic
fields could stimulate osteoblast proliferation.

Electromagnetic

field exposure increased [3H]thymidine incorporation in normal human
mandibular osteoblast-like cells by 26% (Figure 21).

Electromagnetic

field exposure was also shown to stimulate TE85 cell proliferation
(data not shown).
To determine the effects of electromagnetic field exposure on
tyrosyl phosphorylation, TE85 osteosarcoma cells were exposed to
electromagnetic fields generated by 400 milligauss AC + 200 milligauss
DC for 30 minutes.

At zero minutes, 30 minutes, 60 minutes and 90

minutes following electromagnetic field exposure, the cellular levels
of tyrosyl phosphorylation were assessed (Figure 22).

Electromagnetic

field exposure increased the level of tyrosyl phosphorylation of bands
with apparent molecular weights of 220kD and 96kD in a time dependent
manner.

The 220kD band was maximally phosphorylated at 3 hours while

the 96kD band was maximally phosphorylated at 60 minutes.

As

indicated above, mitogenic concentrations of fluoride also increased
the steady state level of tyrosyl phosphorylation of the 220kD and
96kD protein bands.

1 1 7

FIGURE 21. EMF Induced Cell Proliferation. Electromagnetic
field exposure consisted of 400 milligauss alternating current
(AC) + 200 milligauss of direct current (DC) for 30 minutes.
Electromagnetic field exposure of normal human mandibular
cells resulted in a statistically significant increase in
[3H]thymidine incorporation over controls. The error bars
represent SEM with a sample size of 24. Similar results were
also obtained in TE85 cells (data not shown).
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FIGURE 22a. Photograph of autoradiogram showing
Electromagnetic field induced tyrosyl phosphorylation. TE85
cells were exposed to electromagnetic fields for 30 minutes.
The fields consisted of 400 milligauss AC + 200 milligauss DC
and the cells were extracted at the indicated times following
the 30 minute exposure. Electromagnetic field exposure
resulted in increased tyrosyl phosphorylation of proteins
with apparent molecular weights of 220kD and 96kD (indicated
by the arrows on the right side of the photo).

a-insodxa Bmmoiioj sainujiu
06
09
0£
0
3

— SZ£

— S’6^

— 08
— fi’9n

— S0Z

□is m w

02 l

121

FIGURE 22b. Densitometric analysis of autoradiogram showing
electromagnetic field induced tyrosyl phosphorylation. The
shaded area indicates the region in which changes in relative
density do not differ significantly from controls.
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Time Following Exposure

CHAPTER FOUR
DISCUSSION

Based on the previous findings of this laboratory, a potential
biochemical mechanism for the osteogenic action of fluoride has been
proposed (Figure 5, page 33).

This model speculated that the

mitogenic action of fluoride is mediated primarily through a specific
inhibition of an osteoblastic ACP/PTPP by fluoride, which results in
increases in the steady state phosphorylation level of key cellular
phosphotyrosyl mitogenic signaling proteins.

It was hypothesized

that these mitogenic signaling proteins would then signal the
osteoblast cells to proliferate [29].

While the supporting evidence

for this model is strong, it was mostly circumstantial.

In this

regard, direct evidence that fluoride increases tyrosyl
phosphorylation in human bone cells was not yet available.

Therefore,

this dissertation was designed to determine whether mitogenic
concentrations of fluoride could increase the steady state tyrosyl
phosphorylation level of key cellular proteins in human osteoblast1ine cells.
Using a Western immunoblot assay, I was able to demonstrate for
the first time that mitogenic concentrations of fluoride indeed
increased the steady state phosphotyrosyl protein levels of various
cellular proteins in monolayer cultures of human osteoblast-line
cells.

The fluoride-dependent effects on cellular tyrosyl protein

phosphorylation were dose-dependent and time-dependent.
of the effects are noteworthy and could be relevant:
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Three aspects

First, the dose-
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dependent increases in the steady state level of tyrosyl
phosphorylation of a few proteins (i.e., cellular proteins with
apparent molecular weights of 220kD, 34kD and 32kD) appeared to
correspond to the dose-dependent stimulation of cell proliferation by
fluoride.

This circumstantial evidence is consistent with the

speculation that these cellular proteins might be associated with the
proliferative process induced by fluoride.

In support of this are the

observations that some of these proteins also had their level of
tyrosyl phosphorylation increased by bone cell growth factors (see
below).

Nevertheless, further work is required to determine their

potential role(s) in osteoblast-line cell proliferation.
The second intriguing observation is that fluoride induced changes
in the steady state level of tyrosyl phosphorylation of cellular
proteins were only observed in cells which were mitogenically
responsive to fluoride.

In this regard, I have shown that fluoride

did not induce significant alterations in cellular phosphotyrosyl
protein levels in human skin fibroblasts, which do not respond
mitogenically to fluoride [167].

These findings raise an interesting

possibility that increased steady state tyrosyl phosphorylation of
cellular proteins may be a requirement for the mitogenic response to
fluoride.

This speculation is consistent with previous studies which

showed that growth factor induced tyrosyl phosphorylation is closely
associated with mitogenesis, and with the observation that a tyrosyl
protein kinase inhibitor blocked fluoride’s mitogenic activity.
The third interesting finding is that fluoride treatment did not
appear to induce acute increases in the steady state tyrosyl
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phosphorylation levels of cellular proteins in human bone cells.

In

fact, significant increases were detected only after prolonged
treatments with fluoride (i.e., > 8 hours).

The literature indicates

that this time course is not consistent with activation of tyrosyl
protein kinases [81,86].

It is reasoned that if fluoride’s action

were mediated by a direct activation of tyrosyl protein kinase
activity, the effects on phosphotyrosyl protein levels would be
immediate.

In contrast, if the action of fluoride is mediated by an

inhibition of phosphotyrosyl protein dephosphorylation, its effects
would be expected to be slow and accumulative.

The time course of

fluoride dependent increases in tyrosyl phosphorylation is only
consistent with PTPP inhibition.
It is interesting to note that there were no significant increases
in steady state tyrosyl phosphorylation levels until cells were
exposed to fluoride for longer than 8 hours.

In this regard, the

working hypothesis should predict that fluoride treatment would result
in a time-dependent accumulation of phosphotyrosyl proteins beginning
with the initiation of fluoride treatment (assuming that there are
adequate amounts of endogenous growth factors in the conditioned
medium).

However, the assumption that adequate concentrations of

growth factors were available in the conditioned medium during the
initial treatment period may not be valid.

In vitro data suggest that

the mitogenic concentrations of fluoride used for these experiments
are near to the Ki for the ACP/PTPP (the only PTPP activity which has
been shown to be inhibited by fluoride).

Therefore, while it is

probable that fluoride is inhibiting a significant fraction of the
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osteoblastic ACP/PTPP in situ, it is also likely that a large portion
of the enzyme remains active and able to counter the effects of
endogenous growth factors.

It is envisioned that no changes in

tyrosyl phosphorylation would be observed before the concentration of
endogenous growth factors exceeded a certain threshold, and only then
effects of the uninhibited ACP/PTPP would be overwhelmed and increases
in tyrosyl phosphorylation would be observed.

In support of this

speculation are the following; a) when cells were treated with lOOpM
fluoride for 30 minutes followed by lOng/ml IGF-I, increases in
tyrosyl phosphorylation were observed beyond IGF-I treatment alone
(indicating that short exposures of fluoride can increase the level of
tyrosyl phosphorylation when there is a sufficient concentration of
growth factor present, see below), b) untreated cells do not exhibit
changes in tyrosyl phosphorylation for at least 8 hours (suggesting
that even though the cells are releasing endogenous growth factors,
the PTPP activities are not overwhelmed by the amount of growth
factors released over that time frame), and c) vanadate treatment
resulted in immediate increases in tyrosyl phosphorylation (vanadate
is a much more potent inhibitor of the ACP/PTPP than fluoride and an
inhibitor of most PTPP’s which have been described, therefore, one
would expect that a lower threshold concentration of endogenous growth
factors would be required to observe increases in tyrosyl
phosphorylation with vanadate treatment as compared to fluoride
treatment).

One possible interpretation of these data is that

fluoride, at mitogenic concentrations, acts specifically to inhibit
the ACP/PTPP activity, and does not affect the activity of multiple
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PTPP’s like vanadate.

Furthermore, these data are consistent with the

model of fluoride acting as a growth factor enhancer, and not as a
direct mitogen per se.

Additional studies are needed to further

clarify this issue.
It should also be noted that the immunoblot assay used for these
studies has a large intra-assay variation (i.e., when the coefficient
of variation was determined, the maximum was 35%).

Thus, relatively

large increases in tyrosyl phosphorylation were needed for the
increases to be considered significant.

Accordingly, it is possible

that small changes in tyrosyl phosphorylation were not detected in
these experiments.

In light of this, these studies cannot entirely

rule out the possibility that fluoride may have had biologically
relevant acute effects on tyrosyl phosphorylation which could have
been mediated by a direct activation of a tyrosyl protein kinase
activity.

Nevertheless, this possibility may be remote because

previous studies with growth factors whose receptors are tyrosyl
protein kinases (e.g. IGF-I, PDGF, EGF) indicated that acute effects
of tyrosyl protein kinase activation is very large [81,82].

In accord

with this, these studies showed that this immunoblot assay detected
immediate increases in tyrosyl phosphorylation when tyrosyl protein
kinase activators were used.
With regards to the possibility that fluoride might directly
activate tyrosyl protein kinase activity, a recent preliminary report
has suggested that the mitogenic action of fluoride is mediated by
activation of tyrosyl kinase activities [28].

This conclusion was

based on the following pieces of circumstantial evidence: a) A tyrosyl
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protein kinase inhibitor (genistein) appeared to block the mitogenic
action of fluoride and b) treatment with fluoride for 18 hours
appeared to increase the in vitro specific activity of plasma membrane
tyrosyl protein kinases.

However, since it has previously been shown

that the mitogenic action of fluoride on bone cells requires the
presence of a tyrosyl protein kinase activating growth factor [29],
it is also possible that inclusion of a tyrosyl protein kinase
inhibitor could prevent a PTPP-mediated mitogenic response to
fluoride.

Furthermore, since many tyrosyl protein kinases are

activated by tyrosyl phosphorylation,

it is possible that fluoride

could indirectly activate tyrosyl protein kinase activity by
preventing the dephosphorylation of activated kinases.

Further

studies are required to resolve this issue.
Another important finding of these studies was that fluoride’s
effects on cellular tyrosyl phosphorylation were rapidly reversible,
since the removal of fluoride for a brief time (i.e., 1 hour) almost
completely reversed the stimulatory effects of a 23 hour treatment
with fluoride.

This is consistent with the previous observation that

fluoride reversibly inhibits the osteoblastic ACP/PTPP, providing
further circumstantial support for the model of fluoride acting via
PTPP inhibition.

This also suggests that fluoride must be in

continual contact with osteoblasts in order for fluoride dependent
alterations in cellular steady state levels of tyrosyl phosphorylation
to be maintained.

This finding could be clinically relevant.

Presently, many formulations of fluoride used for the treatment of
osteoporosis result in large cyclical variations in serum
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concentrations of fluoride.

While some variation in the serum

concentration of fluoride is inevitable, these data suggest that in
order to have an optimal effect, the serum concentration should be
continuously maintained above the therapeutic threshold, but below the
toxic level.
If the effects of fluoride on steady state phosphotyrosyl protein
levels and on human bone cell proliferation are mediated by a direct
inhibition of PTPP activities, it would be expected that other PTPP
inhibitors should elicit similar effects as fluoride on steady state
phosphotyrosyl protein phosphorylation and cell proliferation in human
osteoblast-line cells.

To evaluate this possibility, the effects of

vanadate on steady state phosphotyrosyl protein phosphorylation and
cell proliferation were investigated in this dissertation.

Vanadate

was chosen for this work because a) vanadate is a well characterized
PTPP inhibitor [138-141], and b) vanadate is also a potent inhibitor
for the osteoblastic fluoride-sensitive ACP/PTPP [29,142].

It was

found that vanadate increased the steady state level of tyrosyl
phosphorylation of several protein bands with apparent molecular
weights similar to those increased by fluoride in human osteoblast
line cells at the doses that stimulated proliferation of the same
cells (244kD, 220kD, 96kD, 62kD, 48kD, 34kD, and 32kD, please see
Table 4).

Accordingly, these findings are consistent with the premise

that fluoride exerted its effects by a direct inhibition of
osteoblastic PTPP activity.
Two additional points can be made on the effects of vanadate as they
are compared to the effects of fluoride:

First, vanadate increased
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Table 4
Factor Dependent Tyrosyl Phosphorylation

Apparent Molecular
Weight

Fluoride

Vanadate

IGF-I

PDGF

EGF

400

++

244

++

++

220

++

++

++

180

++

++

++

++

++

++
++

++

++

++

++
++

106

++
++

++

73

++

++

++

++

68

++

62

++

++

48

++

++

44

++

41

++

38

++

36

++
++

34

++

++

32

++

++

23

++

++

148

96

EMF

++

280

170

IGF-II

++
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the steady state phosphorylation of several proteins in addition to
those which were phosphorylated in common with fluoride (Table 4).
This finding is not entirely surprising because while mitogenic
concentrations of fluoride appear to inhibit primarily the fluoridesensitive ACP/PTPP in bone cells [29], vanadate appears to be a much
broader and general inhibitor of most cellular PTPPs.

In this regard,

it may be speculated that at least some of the cellular proteins whose
tyrosyl phosphorylation was increased by fluoride could be cellular
substrates of the fluoride-sensitive ACP/PTPP, whereas those cellular
proteins whose tyrosyl phosphorylation was increased by vanadate but
not by fluoride, are not likely to be cellular substrates for this
enzyme.
The second salient point is that while most of the stimulatory
effects of vanadate, like those of fluoride, were accumulative and
prolonged, vanadate, unlike fluoride, also appeared to induce acute
increases in the steady state level of tyrosyl phosphorylation of some
cellular proteins.

The significance of these acute effects of

vanadate on tyrosyl phosphorylation is not clear at the present time.
However, it should be pointed out that vanadate could directly
activate certain tyrosyl protein kinase activities in addition to
primary actions of inhibiting PTPP activities [141].

Therefore, the

acute effects of vanadate may simply reflect the direct stimulation of
tyrosyl protein kinases by vanadate.

Nevertheless, because both

fluoride and vanadate at mitogenic concentrations increased the steady
state level of tyrosyl phosphorylation of similar cellular proteins,
these findings are consistent with the interpretations that the
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mitogenic effects of fluoride may be mediated by inhibition of PTPP
activities and that some of these cellular phosphotyrosyl proteins may
be associated with the mitogenic process. These data are in agreement
with the observations that both vanadate and fluoride were shown to
inhibit the osteoblastic ACP/PTPP at the same concentrations which
stimulated tyrosyl phosphorylation.
If these cellular phosphotyrosyl proteins indeed play a role in
mediating the cell proliferative process in human bone cells, one may
expect that other bone cell mitogens could also increase the steady
state phosphorylation levels of these same proteins.

To evaluate this

hypothesis, I have examined the effects of three additional classes of
bone cell mitogens on steady state phosphorylation levels of cellular
proteins: a) growth factors whose receptors contain intrinsic tyrosyl
protein kinase activity (IGF-I, PDGF and EGF), b) a growth factor
whose receptor is not a tyrosyl protein kinase (IGF-II), and c) a bone
growth stimulating agent whose mechanism is undefined (electromagnetic
fields).
Three different growth factors (i.e. IGF-I, PDGF, and EGF) were
chosen for the first group because a) it is believed that these growth
factors have their mitogenic effects mediated by tyrosyl
phosphorylation, and b) the structural features of the receptors for
these factors belong to three different subgroups (i.e. IGF-I to group
II, PDGF to group III and EGF to group I, see page 19 for details).
IGF-II was chosen for the second class because it is the most
abundant, and apparently the most physiologically important, growth
factor in human bone cells [143].

Electromagnetic field exposure was
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selected as an example for the final class because a) electromagnetic
fields have been used to treat non-union bone fractures [156], and b)
electromagnetic field exposure has been shown to stimulate human bone
cell proliferation in vitro [154,155,157].
The comparison of the cellular phosphotyrosyl proteins whose
phosphorylation levels were increased by these agents is summarized in
Table 4.

It was determined that the proteins which were tyrosyl

phosphorylated in response to IGF-I appeared to also be tyrosyl
phosphorylated in response to fluoride treatment (220kD and 96kD,
based on apparent molecular weights).

Interestingly, these studies

showed that fluoride was able to directly interact with the IGF-I
dependent tyrosyl phosphorylation cascade.

This conclusion was drawn

because IGF-I dependent tyrosyl phosphorylation of a 170kD band was
detected at 30 minutes with IGF-I alone, however, in a separate
experiment, when cells were pretreated with fluoride, IGF-I dependent
tyrosyl phosphorylation of the 170kD band was detected after only 5
minutes.

While the physiologic significance of this effect is

unclear, this observation is consistent with previous observations
that fluoride potentiates the mitogenic action of IGF-I in human
osteoblast-line cells [22].

PDGF stimulated tyrosyl phosphorylation

of two proteins with similar molecular weights as those phosphorylated
by fluoride, 244kD and 220kD, while EGF induced changes in tyrosyl
phosphorylation of four proteins with similar molecular weights as
those phosphorylated by fluoride (244kD, 220kD, 170kD and 96kD).
With respect to IGF-II, these studies showed for the first time
that treatment of human osteoblast-line cells with homogeneously pure
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IGF-II increased tyrosy! phosphorylation of protein bands with
apparent molecular weights of 400kD, 280kD, 220kD and 96kD.

These

data are intriguing because they indicate that even though the IGF-II
receptor does not contain intrinsic tyrosyl protein kinase activity,
IGF-II is capable of altering the balance between tyrosyl protein
kinase and PTPP activities in osteoblast-line cells.

The fact that

IGF-II induced tyrosyl phosphorylation of a protein with an apparent
molecular weight of 96kD is interesting because this is approximately
the molecular size of the beta subunit of the IGF-I receptor.

This

raises the possibility that IGF-II may act to increase
autophosphorylation of the IGF-I receptor.

However, the time course

for tyrosyl phosphorylation of the 96kD protein band induced by IGF-II
was markedly different from that induced by IGF-I, in that IGF-II
elicited slow and prolonged effects while IGF-I elicited immediate and
short term effects on the level of tyrosyl phosphorylation of the 96kD
protein band.

Furthermore, IGF-II dependent tyrosyl phosphorylation

included two protein bands which did not undergo detectable increases
in tyrosyl phosphorylation in any experiment involving IGF-I
treatment.

One possible interpretation of these data is that if IGF-

II did activate the IGF-I receptor, it either altered its substrate
specificity or activated an additional tyrosyl protein kinase activity
which was responsible for the phosphorylation events not shared in
common with IGF-I treatment.

Further investigations into the nature

of IGF-II dependent tyrosyl phosphorylation are currently underway in
our laboratory.
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With respect to electromagnetic field exposure, these studies also
showed for the first time that low intensity electromagnetic field
exposure was capable of increasing the steady state level of tyrosyl
phosphorylation of protein bands with apparent molecular weights of
220kD and 96kD (Table 4).

While more studies are needed to determine

the significance of these observations, they raise the interesting
possibility that the effect of electromagnetic field exposure to
increase osteoblast proliferation may also be associated with and/or
dependent on tyrosyl phosphorylation.
While the overall patterns of changes in tyrosyl phosphorylation
induced by these bone cell mitogens were remarkably consistent, there
was some variability in effector induced phosphorylation patterns from
experiment to experiment.

The reason(s) for this is unknown, however,

it may be speculated that one or more of the following variables might
be contributing factors;

a) the cell cultures used for these studies

were made up of mixed cell populations, b) endogenous growth factor
production could have been different in type and/or amount, c) the
cells might not have been completely synchronized, d) the time at
which the cells were extracted may have been inappropriate to observe
some of the changes, c) artifacts prevented analysis of certain parts
of some autoradiograms, and e) as mentioned before (page 112), the
changes in phosphorylation may have been occurring at levels which
were undetectable by this immunoblot assay.

In keeping with this,

only factor-dependent changes in tyrosyl phosphorylation which
occurred at significant levels for more than one time point, more than
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one dose, or were repeated in separate experiments, were included in
Table 4.
A review of the data summarized in Table 4 reveals that all the
tested bone cell mitogens increased the steady state level of tyrosyl
phosphorylation of a protein band with an apparent molecular weight of
220kD.

Since the bone cell mitogens used for these studies are

believed to stimulate cell proliferation by different mechanisms
[i.e., tyrosyl protein kinase/PTPP mediated (vanadate), receptor
tyrosyl protein kinase mediated (IGF-I, PDGF and EGF), receptor
mediated with no intrinsic tyrosyl protein kinase activity (IGF-II)
and unknown (EMF)], our data support the hypothesis that the 220kD
protein may be involved in regulating osteoblast-line cell
proliferation.
The identity of the 220kD protein is unknown, however, a number of
cellular phosphotyrosyl proteins have been identified to date, and
several of these are summarized in Table 5.

It should be emphasized

that the molecular weight assignment of 220kD is approximate since the
highest molecular weight standard available for these studies was
205kD.
It is interesting to speculate that the 220kD protein could be one
of the three proteins with molecular weights greater than 200kD shown
in Table 5.

These include; a) tensin, a 200kD cytoskeletal protein

which has an SH2 domain and affects actin filament formation [92],
b) talin, a 225kD cytoskeletal protein which has a low affinity for
the fibronectin receptor, integrin [92], and c) the IGF-II receptor, a
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TABLE 5.
Molecular Weight and Possible Identification of
Phosphoty rosyl Proteins.

M.W.-ldentity

Description and Function

34kD - p34 cdc2

p34^‘?is a ubiquitious serine/threonine kinase [92,168] which combines with
cyclin b (45-62kD) to form MPF (n phase promoting factor or maturation promoting
factor) [169]. MPF controls entry into M phase in eukaryotic cells
[89,170,171,172]. The enzyme is inhibited by phosphorylation of tyrosine-15 and
must be dephosphorylated to function [89,92,173,174]. Tyrosine-15 is locat
ed within the ATP binding site [92]. p80^^ is involved in the dephosphorylation which activates MPF [92,175,176]. Cyclin b accumulates during interphase,
increasing the concentration of the cyclin/p34^complex [1 75,1 77]. p107^
is a serine/threonine and tyrosine kinase which promotes the tyrosyl phosphory
lation of p34f^ [89,92,1 78,179]. mikl gene product also phosphorylates
p34^[89]. p54^#activates MPF by inducing dephosphorylation of the MPF
complex [92,174,180,181 ]. p34^ is also associated with p65 PTPP [182].
p85^',w is phosphorylated by p34^ kinase on serine 47 [183]. Mutation of
tyrosine-15 to phenylalanine results in premature onset of mitosis [92]. [see
review, 184]

42kD - MAP2 kinases

Serine/threonine kinases which phosphorylate microtubule associated protein 2
(MAP2) [71,92,185]. May play a role in the transition from slender to stumpy
forms during life cycle of Trypanosoia brucei, and its phosphorylation appears
to be elevated by vanadate treatment [186]. Appears to receive signals from
both tyrosine kinases and PKC [183].

60kD - pp60 src

pp60^ is a substrate for the EGF receptor and is itself a tyrosyl protein
kinase (non-receptor) [91,95,96].

62kD - ??

Prominent substrate of pp60y'src and tyrosyl phosphorylation correlates with vsrc transforming activity [187].

72kD or 74kD - Rafl

A serine/threonine kinase important in mediating signals for cells to prolifer
ate. Becomes transiently associated with the PDGF receptor. May be tyrosyl
phosphorylated by the PDGF receptor and direct tyrosyl phosphorylation correlat
ed with Rafl kinase activation, however, the role of tyrosyl phosphorylation of
Rafl is not known, and very little of the total amount of Rafl in cells is
tyrosyl phosphorylated [92], Two MJ. may arise because of phosphorylation
events in that the 72kD form appears in the abscence of EGF and the 74kD form
arises with EGF treatment [188].

95kD-insulin receptor The insulin receptor is composed of two alpha subunits (135kD each) which bind
to insulin and two beta subunits (95kD each) which contain the tyrosyl kinase
activity and are autophosphorylated when insulin is bound [189]. Each beta sub
unit is phosphorylated on 5 tyrosyl residues - 3 reside in the kinase homology
region and 2 are at the carboxy terminal tail [190,191],

138

TABLE 5 (cont)
M.W.-ldentity

Description and Function

96kD - IGF I receptor The IGF I receptor is a 450kD [153] subclass II receptor tyrosyl protein kinase
[86], and 96kD represents the autophosphorylating |3 subunit [81]. IGF-I induced
cell proliferation appears to be dependent on the tyrosyl protein kinase activi
ty of its receptor.
120kD - GAP

Tyrosyl phosphorylation of GAP (GTPase activating protein) may inhibit its
activity [183]. Overexpression of GAP inhibits transfonation by src [92]. GAP
appears to be non-covalently associated with p190 and p62 (other phosphotyrosyl
proteins) [187].

145kD - p145MET

P145HET is the beta chain of the MET protooncogene product (the alpha chain is
50kD). p145NET is rapidly phosphotyrosyl dephosphorylated by calcium - calcium
negatively modulates p145NET kinase activity through a serine phosphorylation
mediated by a calcium activated serine kinase distinct from protein kinase C
[192].

150kD - PLC gamma 1

Phospholipase C gamma 1 (PIC gamma 1) [92] catalyzes the breakdown of phosphati
dylinositol 4,5-bisphosphate to diacylglycerol (an activator of protein kinase
C) and inositol 1,4,5-triphosphate (a mobilizer of stored calcium) [92]. Tyro
sine phosphorylation of phospholipase C gamma 1 activates it by several fold
[92].

170kD - EGF receptor

The EGF receptor [87] is a transmembrane glycoprotein whose kinase activity
correlates with receptor dimerization [193]. Especially abundant in A431 cells
(most cells have 10 -105 receptors, but A431 cells have approximately 106 EGF
receptors/cell). It has been shown that EGF induced cell proliferation is
entirely dependent on the tyrosyl protein kinase activity of its receptor [87].

180kD - PDGF receptor The POGF receptor [147] is a subclass III tyrosyl protein kinase receptor [86]
whose tyrosyl kinase activity has been shown to be necessary for PDGF induced
cell proliferation [83].
200kD - tensin

Tensin is an actin binding protein which has an SH2 domain [92].

225kD - talin

Talin is a cytoskeletal protein which interacts with integrin [92].

220-250kD - IGF-IIr

One of the functions of the IGF-II receptor (IGF-IIr) may be to stimulate calci
um influx by G-protein interactions [151]. Neutralizing IGF-II receptor anti
bodies were shown to block both IGF-I and IGF-II induced osteoblast cell prolif
eration [46],
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220-250kD protein for which tyrosyl phosphorylation plays an unknown
function [153].
While it is plausible to speculate that cytoskeletal proteins may
undergo alterations in their levels of tyrosyl phosphorylation as a
means to regulate changes in cell morphology (i.e., transformation,
mitosis, etc), to date, no correlation has been shown between the
phosphorylation status of either tensin or talin and cell morphology
[92].

Furthermore, if tyrosyl phosphorylation was determined to play

a role in regulating the actions of tensin and talin, it would
presumably be most important when cells were undergoing major changes
in their cytoskeleton (i.e., mitosis).

While this could be related to

cell mitogenesis, the time courses of the changes in the
phosphorylation status of the 220kD protein argues against it being a
cytoskeletal protein, since it was phosphorylated immediately by
growth factor receptor tyrosyl protein kinases (presumably when cells
were resting in G1, and not altering their cytoskeleton).
The possibility that the 220kD protein may be the IGF-II receptor
is intriguing and makes teleological sense in light of the fact that
IGF-II is the most abundant growth factor both produced by bone and
found in bone matrix.

This is consistent with previous findings that

neutralizing anti-IGF-II receptor antibodies not only inhibited IGF-II
induced osteoblast proliferation, but also inhibited IGF-I induced
osteoblast proliferation as well [46].

Additional studies will be

required to determine whether this 220kD protein is, in fact, the IGFII receptor, and to determine how IGF-II is capable of inducing
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tyrosyl phosphorylation when its receptor has no tyrosyl protein
kinase activity.
In conclusion, these studies have advanced our understanding of
the regulation of human bone cell proliferation by fluoride.

Our data

represent the first conclusive evidence that fluoride increases steady
state levels of tyrosyl phosphorylation in human osteoblast-line
cells.

The observed dose- and time-dependent changes in fluoride

induced tyrosyl phosphorylation are consistent with the previously
proposed model that fluoride is acting to stimulate osteoblast
proliferation by inhibiting a specific osteoblastic ACP/PTPP,
resulting in the generation of a tyrosyl phosphorylation mitogenic
signal.

Definitive evidence for the physiologic function of the

ACP/PTPP will await genetic alteration experiments in which the
effects of knocking out the gene for this enzyme, and/or over
expression of the enzyme, on human osteoblastic proliferation will be
determined.

Finally, the intriguing question of the possible

involvement of the 220kD protein in the cell proliferative process
requires the identification and characterization of that protein.
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